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ABSTRACT 
 
 
Macromolecular complexes of cystic fibrosis transmembrane conductance 
regulator (CFTR) comprise of network of proteins that can regulate cAMP-/cGMP-
activated CFTR chloride channel function. We report the physical and functional 
coupling of CFTR with nitric oxide (NO) producing enzyme-inducible nitric oxide 
synthase (iNOS) at the apical plasma membrane in inflammatory bowel disease (IBD). 
The complex formation requires the scaffolding protein Na
+
/H
+
 exchanger regulatory 
factor 2 (NHERF2). We demonstrate that iNOS is overexpressed at or near the apical 
plasma membrane of gut epithelial cells in IBD and, through the stimulation of the NO-
cGMP pathway, generates compartmentalized cGMP underneath the plasma membrane. 
This action triggers the hyperactivation of CFTR chloride channels and causes secretory 
diarrhea phenotype in IBD. Inhibition of CFTR and iNOS activity attenuates diarrhea in 
dextran sodium sulfate (DSS) induced colitis. Dissolution of the macromolecular 
complex in Nherf2
 -/- 
mice renders them resistant to CFTR-mediated secretory diarrhea in 
murine colitis models compared to Nherf2
+/+
. Our findings have important therapeutic 
implications in IBD and other forms of gastrointestinal inflammations. 
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CHAPTER 1.    COMPARTMENTALIZED CYCLIC NUCLEOTIDE 
SIGNALING 
 
 
Introduction 
 
Cyclic nucleotides are the cellular messengers that relay environmental cues to 
mobilize cellular responses. Important cyclic nucleotides inside the cell are cyclic  
adenosine-3′,5′-monophosphate (cAMP) and cyclic guanosine-3′,5′-monophosphate 
(cGMP) (1). These cellular messengers are now known to be involved in various cellular 
responses to hormones and other types of stimuli and thereby, control diverse functions 
(e.g., metabolism, cell proliferation, differentiation, migration and fluid secretion) (2). It 
was first noticed by Bruxton and Brunton in 1980s that there is differentiation of cAMP-
dependent signaling processes in the cardiac myocytes (2-4). This concept came to be 
formulated as compartmentalized signaling. At the molecular level, compartmentalized 
cellular signaling would mean local sinks of cellular messengers capable of regulating 
signaling events in a nodal manner inside the cell. A signaling process gets 
compartmentalized when there is a generation of cyclic-nucleotides in the vicinity of their 
effectors and the signal termination mechanisms are set in place to prevent the spatial 
spread of the signaling. The receptors include protein kinases, kinase anchoring proteins, 
guanine-nucleotide exchange factors and cyclic-nucleotide-gated channels (1). 
Termination of the signaling process usually involves cyclic-nucleotide catabolizing 
enzymes phosphodiesterases (PDEs) and in some cases, recently characterized cyclic-
nucleotide efflux transporters (2, 5). The typical advantage of the process of 
compartmentalization is the spatiotemporal regulation of cyclic-nucleotide responsive 
proteins in specialized microdomains allowing high velocity and specificity of the 
responses. Apparently, compartmentalized signaling came into existence as an 
evolutionary response to selection pressure as eukaryotic cells needed to respond rapidly 
to the changing conditions and segregate simultaneously running signaling processes. 
 
 
Compartmentalization of cAMP Signaling 
 
 
Adenylyl cyclases and G protein coupled receptors initiate cAMP compartments 
 
Generation of cAMP from ATP is dependent upon G-protein-coupled-receptor 
(GPCR)-mediated stimulation of adenylyl cyclases (ACs) (3, 6). It has been observed that 
certain membrane-bound AC isoforms can be selectively delivered to membrane rafts 
(rafts are dynamic cholesterol and sphingolipids rich structures of plasma membrane that 
play an important role in segregating signaling cascades at the membrane) where they 
exhibit exquisite sensitivity for local sub-micromolar Ca
2+
 gradients (7). The soluble ACs 
also exhibit compartmentalized distribution in close proximity with cAMP-responsive 
proteins and have been found to closely communicate with localized bicarbonate 
gradients (8). There are also reports on AC6 communicating with GPCRs β1/ β2-
Adrenergic receptors (ARs) in caveolin-rich domains of plasma membrane with the 
   2 
coupling efficiency varying as a function of external stimulus (9). The selective patching 
of AC-GPCR signaling with an inherent role of heterogeneous physical barriers and with 
the contribution of cytoskeletal elements, provides the first level of cAMP-
compartmentalization. 
 
 
Phosphodiesterases and A-kinase anchoring proteins  
 
In view of high diffusion rates of cAMP (~220 μ meters s−1), it is of utmost 
interest to know how cAMP mediated responses remain highly localized and specific (2, 
10). There are mechanisms to annul cAMP generated inside the cell and in fact, the 
cAMP hydrolysis has been estimated to be occurring faster than the cAMP synthesis (11). 
PDEs constitute the major force of catabolizing cyclic nucleotides. PDEs break the 
phosphodiester bond in cAMP and cGMP resulting in the formation of adenosine-5-
monophosphate (AMP) and guanosine-5-monophosphate (GMP), respectively. There are 
eleven mammalian PDE gene families, three cAMP-specific (PDE4, PDE7, and PDE8), 
three cGMP-specific (PDE5, PDE6, and PDE9), and five exhibit dual-specificities 
(PDE1, PDE2, PDE3, PDE10, and PDE11) (2). The diversity and specificities of PDE-
regulated signaling are derived from the variability of different isoforms in tissue-type 
expression, subcellular localization, and specific associations with adaptor and effector 
proteins (12). FRET-based sensors which fundamentally comprise of genetically 
modified cAMP-effectors such as EPAC and PKA subunits are immensely valuable for 
studying PDE-mediated compartmentalized signaling (13). Based on studies using these 
cyclic nucleotide sensors, it has been shown that pharmacological inhibition of PDEs 
does not alter the global levels of cyclic messengers but rather their sub-cellular 
distribution. It is now accepted that concerted actions of ACs and PDEs can create 
localized gradients of cAMP (3). This concept gets more sophisticated with an incurred 
process of GPCR desensitization because of the major regulatory role of PDE. For 
example, PDE4D5 can dampen β2-AR signaling upon β-arrestin mediated recruitment of 
the enzyme to the phosphorylated β2-AR. β-arrestins uncouple β2-AR from Gs, essential 
for β2-AR desensititzation (3). PDE4D5- β-arrestins complex will apparently accelerate 
the process of desensititzation where uncoupling of β2-AR from Gs will occur 
concurrently with cAMP degradation by PDE4D5 and prepare β2-AR for another round 
of agonist-induced activation (3). PDE3 inhibitor cilostazol can potentiate cystic fibrosis 
transmembrane conductance regulator (CFTR) Cl
-
 channel function as PDE3A directly 
interacts with CFTR at the apical surface in epithelial cells (4). Notably, PDE3 inhibition 
generates compartmentalized cAMP at the plasma membrane causing highly localized 
activation of CFTR Cl
-
 channel function.  
 
It has been found that PDEs can localize to specific subcellular domains via 
binding to A-Kinase anchoring protein (AKAP) (14). AKAP recognizes the N-terminal of 
regulatory subunit II of cAMP-activated protein kinase A (PKA) and tethers PKA at 
distinct subcellular locations allowing spatiotemporal regulation of PKA substrates (3). 
Certain PDEs, AKAPs, kinases and phosphatases have analogous targeting mechanisms 
(specific for protein-protein or protein-lipid interactions) (3). PDE4D3 and PKA run a 
concerted negative feedback loop for cAMP signaling onto a muscle specific AKAP 
   3 
(mAKAP) maintained signaling module that controls the output of ventricular 
hypertrophy (15). Neuronal anchoring protein AKAP79 was found to bind to the 
phosphatase calcineurin and diminish the phosphorylation of PKA substrates and later, to 
protein kinase C (PKC) which can act on an overlapping but distinct set of substrates (16, 
17). Also, AKAPs exhibit discrete subcellular targeting where they can nucleate distinct 
protein complexes. The plasma membrane-associated Yotiao, a smallest splice variant of 
the AKAP9 family tethers PKA, protein phosphatase 1, PDE4D3, the NR1 subunit of the 
NMDA receptor, IP3 receptor, and the K
+
 channel subunit KCNQ1 to control IKs currents 
in the heart (18). Ezrin is an AKAP enriched in microvilli on the apical side of polarized 
epithelial cells which regulates the PKA-mediated inhibition of Na
+
/H
+
 exchanger 3 
(NHE3) and activation of CFTR via Ezrin-binding protein Na
+
/H
+
 exchange regulatory 
factor 1 (NHERF1) (19-22). Ezrin also binds F-actin which determines the stability of 
CFTR at the plasma membrane (23). Thus, AKAPs assemble large multi-protein 
complexes which act as nodes of enzymatic and regulatory activities. 
 
 
Multiple drug resistance proteins: cyclic nucleotide efflux transporters 
 
Davoren and Sutherland observed that hormonal stimulation of the cells would 
alter not only the intracellular but also the extracellular cAMP levels (2). To explain this 
observation, it was rationalized that cells use an unidentified cyclic nucleotide export 
system. Later, a member of the ABC transporter family termed as multidrug resistance 
protein 4 (MRP4; also known as ABCC4), was identified to efflux cAMP as well as 
cGMP (24, 25). The affinity constant of MRP4 for cGMP (10μM) is lower than for 
cAMP (45μM) (25).  
 
MRP4 is ubiquitously expressed in many cell types polarized and non-polarized 
and in the former type lines both apical and basolateral membranes of the epithelial cells 
(2). Interestingly, MRP4 inhibition alone could not substantially change the total cyclic 
nucleotide levels, which clearly signifies the role of MRP4 in compartmentalized 
signaling. Li et al. reported an important role of apical MRP4 in regulating CFTR 
function in a highly compartmentalized manner in the gut epithelial cells (5). Recent 
studies reported that MRP4 can be anchored by caveolins in the plasma membrane where 
it participates in highly segregated signaling modules (26). We recently demonstrated that 
MRP4 can control distinct PKA activities at the leading vs. lagging edge of a migrating 
fibroblast to regulate the migration process (27). Also, regulation of migration gets 
biphasic as MRP4 segregates between cAMP and cGMP-mediated signaling and directs 
different migration outputs (27). Other additional ABC transporters have been identified 
to export cyclic nucleotides which include MRP5, ABCG2 and MRP8 (2). Therefore, 
cyclic nucleotide extrusion from the cell by certain ABC transporters represents an 
additional mechanism to attenuate the signaling process and also, there have been 
observations fostering the fact that these two mechanisms may act compensatory or in 
concert (2).  
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Compartmentalization of cGMP Signaling 
 
Studies related to elucidating cGMP signaling are less well-understood compared 
to the cAMP pathways. Robert F. Furchgott, Louis J. Ignarro and Ferid Murad won 1998 
Nobel Prize in Physiology or Medicine for studying the significance of nitric oxide (NO)-
cGMP pathway in cardiovascular health which underscores the importance of cGMP 
pathways in the living systems. cGMP plays role in several important biological 
functions such as vascular tone regulation, epithelial electrolyte transport, migration, 
neurotransmission and immunomodulation (28). cGMP is synthesized by NO-responsive 
soluble (sGC) or membrane-associated particulate (pGC) form of guanylyl cyclases. 
Seven isoforms of pGCs have been identified which include natriuretic peptide receptors 
GC-A and GC-B, GC-C which are responsive to bacterial heat-stable enterotoxins, 
guanylin, and uroguanylin and orphan receptors GC-D to G (28). The process of cGMP 
compartmentation is vaguely known compared to cAMP however; the same question can 
be applied asking how different extracellular cues fundamentally working through a 
common intracellular messenger can produce varied biological responses. It is likely, that 
similar mechanisms and components to enable compartmentalization of cGMP signaling 
would exist as are known for cAMP. Recent studies report that GC-C communicates with 
intracellular p21-activated kinase via Rac GTPase to regulate cell migration and actin 
cytoskeletal restructuring (29). The basis of this process would be asymmetric and 
segregated signaling that regulates the directed cell migration (27, 29). cGMP-dependent 
protein kinases (PKGs) are the most important effectors of cGMP response. G-kinase 
anchoring proteins (GKAPs) are the proteins required for the dissemination of PKG-
signaling. However, the field is very new and limited information is available. 
Scaffolding protein NHERF2 has been shown to function as (GKAP) to mediate cGMP-
dependent regulation of NHE3 allowing the compartmentalized regulation of the protein 
(30). Since cGMP can increase CFTR chloride activity and it is known that CFTR can 
bind to NHERF2, NHERF2 can regulate cGMP-dependent activation of CFTR which 
would also likely to be occurring in membrane restricted compartments. Few other 
GKAPs include vimentin, guanylate cyclase A, troponin T, myosin light chain kinase, 
testicular golgi protein GKAP42 (30). Neutralizing components of cGMP signaling 
importantly include cGMP catabolizing PDEs: PDE5, PDE6, and PDE9. Five PDEs 
(PDE1, PDE2, PDE3, PDE10, and PDE11) exhibit dual specificities for cAMP and 
cGMP. These dual-specificity PDEs (in particular reported to be PDE2 and PDE3) play 
critical roles in cross-talks between cGMP and cAMP-dependent signaling (31, 32). An 
important role of spatiotemporal regulation of functional NO-cGMP signaling system has 
been described in cell fate decisions and lineage determination during the early 
differentiation process of embryonic stem cells (33). 
 
In this study we determine how compartmental cGMP becomes the 
pathophysiological basis of CFTR-dependent diarrhea in inflammatory bowel disorders 
(IBD). We elucidate formation of a CFTR-containing macromolecular complex as the 
molecular basis of diarrheal phenotype of IBD. 
 
In conclusion, the concept of compartmentalized signaling as of today is 
astonishingly advanced and intricate. This is primarily attributed to appreciating how the 
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process of compartmentalized signaling is fundamentally relevant to cellular behavior in 
health and disease and the availability of scientific tools which allow monitoring the 
process very efficiently. 
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CHAPTER 2.    MACROMOLECULAR COMPLEX OF CFTR AND 
INDUCIBLE-NOS AT THE PLASMA MEMBRANE IN INFLAMMATORY 
BOWEL DISEASES 
 
 
Cystic Fibrosis Transmembrane Conductance Regulator 
 
Compartmentalized signaling has been shown to extensively regulate the activity 
of Cl
-
 channel CFTR (or ABCC7) at the plasma membrane (34, 35). CFTR  is a 1480 
amino-acid long membrane-bound protein belonging to the ATP-binding cassette 
transporter (ABC) superfamily which consumes energy from ATP hydrolysis to transport 
a wide-variety of substrates (34, 35). CFTR consists of two homologous halves, each 
composed of a hydrophobic membrane-spanning domain (MSD) containing six 
transmembrane helices and a cytosolic nucleotide binding domain (NBD). The two NBDs 
are linked by a cytoplasmic regulatory domain (R domain) which contains multiple 
consensus phosphorylation sites for several kinases. The phosphorylation state of CFTR 
determines the channel open probability (P). The structure of CFTR is shown in Figure 
2-1. 
 
Interestingly, it was reported that the amino (N) terminus cytoplasmic region of 
CFTR is involved in a direct interaction with the R domain via a conserved set of 
residues which will determine the steady-state activity of CFTR (36). CFTR is an 
epithelial cell protein present on the apical membranes in the gut, lung airways, sweat 
gland, pancreas and urogenital tract that regulates fluid balance across the epithelia lining 
these organs (37).  
 
 
Macromolecular Complexes of CFTR 
 
CFTR is a cAMP-/cGMP-activated Cl
-
 / HCO3
-
 transporter (38, 39). The most 
interesting aspect of CFTR regulation is the formation of multi-protein complexes via its 
N and carboxyl (C) terminals. A direct interaction at the N terminus of CFTR with the 
regulatory SNARE ( soluble N-ethylmaleimide-sensitive-factor attachment protein 
receptor) protein Syntaxin 1A negatively modulates CFTR function and is subject to 
competitive inhibition by Syntaxin 1A–binding protein Munc 18 (40). Such interactions 
will be critical to regulate the dynamics of CFTR channel activity according to a 
physiological cue. Macromolecular complexes of CFTR involving regulators and 
effectors of cAMP would lead to highly compartmentalized regulation of CFTR within 
cAMP microdomains at the plasma membrane. The cAMP-elevating ligand adenosine 
(ADO; 1-20 μM) which acts through adenosine receptor subtypes belonging to GPCR 
family can also stimulate CFTR-mediated Cl
-
 currents in a compartmentalized manner at 
the apical cell membrane of polarized epithelial cells (41). In cell-attached single-channel 
recordings of CFTR, it was observed that the AC stimulating agent forskolin (Fsk), or 
cell-permeant cpt-cAMP always elicited a global cAMP response and activated CFTR 
irrespective of whether these reagents were applied in the pipette or in the bath (42). In 
contrast sub-micromolar concentrations of ADO evoked a localized activation of CFTR, 
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Figure 2-1. Structure of CFTR protein 
 
CFTR protein topology showing various domains of the CFTR protein: two membrane 
spanning domains (colored in orange), two nucleotide binding domains (colored in red) 
and a regulatory domain (colored in light blue). 
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as ADO when added to the bath failed to activate CFTR function (42).  
 
 
PDZ-scaffolds 
 
Most of the macromolecular formations of CFTR at the C terminus are mediated 
by a class of scaffolding proteins termed as PSD-95/DLG-5/ZO-1 (PDZ)-domain proteins 
(34, 37). PDZ domains are named after the first three identified PDZ-domain containing 
proteins which include postsynaptic density protein-95 (PSD-95), the drosophila 
junctional protein Disc-large (DLG), and the epithelial tight junction protein zonula 
occludens (ZO)-1. PDZ modules are small approximately 90 amino-acids long and 
recognize four to six residues of the target proteins. PDZ domains constitute among the 
most commonly expressed domains in an eukaryotic genome and have been estimated to 
number greater than 400 in human (43). With such an abundance and diversity, PDZ-
proteins apparently regulate many signal transduction events inside the cell (44). The 
primary role of PDZ proteins is to function as scaffolds to assemble large protein 
complexes that facilitate coordination and cross-talk within the same or even distinct 
pathways.  
 
Elucidation of the structures of a number of PDZ domains alone, or in the ligand-
bound state have provided valuable insights into how auxillary structural components of a 
globular protein in an interaction with an adaptor protein modulate the activity of the core 
domain (45). The canonical structural configuration of PDZ domains comprises 6 β-
strands (βA ~ βF), a short α-helix (αA) and a long α-helix (αB). Single hydrophobic cleft 
between the αB-helix and βB-strand structures, with the highly conserved carboxylate-
binding loop (R/K-XXX-G-Φ-G-Φ motif, where X is any amino acid residue and Φ is a 
hydrophobic residue) located before the βB strand, forms the peptide-binding site (44). 
Several modes of regulation and deregulation of PDZ-dependent interactions have been 
identified which include phosphorylation of the PDZ-binding motif in the target proteins, 
formation of disulphide linkages with in the PDZ-proteins, occupancy of the peptide-
binding cleft by an inbuilt PDZ-binding motif and allosteric inhibition (44).  
 
With the ability of PDZ-proteins to regulate a huge web of signal transduction 
events, many of them have now been implicated in cancer and neurodegenerative 
disorders (46). This is based on the studies in animal models and using blocking peptides 
to competitively inhibit native interactions which identified that certain PDZ-proteins 
integrate disease-associated proteins. The obvious advantage of targeting scaffolding 
proteins is the simultaneous control of multiple signaling cascades in complex diseases 
by hitting a single protein rather than multiple disease-related proteins. Subtle-binding 
specificities of PDZ-domains have been moderately classified. Also, mapping of the PDZ 
domains and narrowing down to smaller binding segments would confer a high degree of 
specificity and flexibility in the use of such therapeutic approaches. The bigger challenge 
in the future in using PDZ-interaction modules as drug targets is the promising in vivo 
outcome and the ease of manipulation of this approach without any significant side 
effects. 
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CFTR macromolecular complexes on PDZ-scaffolds 
 
CFTR possesses a class I PDZ-domain binding motif DTRL-COOH at the C 
terminus that mediates the binding of CFTR to several PDZ-domain proteins, including 
Na
+
/H
+
 exchange regulatory factor 1 (NHERF1), NHERF2, CFTR-associated protein 70 
kDa (CAP70; also known as PDZK1), NHERF4 and CFTR-associated ligand (CAL) 
(47). Various PDZ-mediated interactions of CFTR and their implications are shown in 
Figure 2-2.  
 
PDZ-proteins are usually bivalent or multivalent harboring multiple PDZ-
domains. This structural feature of PDZ-proteins is known to contribute to CFTR-
dimerization and most interestingly, constitution of large multiple protein complexes 
which act as hubs of enzymatic and regulatory activities (48, 49). Also, the crosslinking 
between two CFTR molecules or CFTR and other interacting proteins can be modulated 
by the stoichiometry of CFTR-PDZ-protein interaction (48). Few studies also suggested 
that CFTR dimerization is only cAMP-regulated and does not require NHERF proteins 
(50). Other roles of PDZ-mediated interactions of CFTR have been identified which 
include trafficking, polarized expression and membrane-associated mobility and 
stabilization of the protein (34). 
 
 
CFTR is coupled to β2 adrenergic receptor signaling via the formation of a NHERF1-
mediated macromolecular complex with β2 adrenergic receptor at the plasma membrane 
 
CFTR couples β2-AR via NHERF1 at the apical surface of epithelial cells (22). 
NHERF1 recognizes Ezrin (an AKAP) via its ezrin/radixin/moesin (ERM) domain at the 
C-terminus that positions PKA close to CFTR. On agonist activation of the receptor, AC 
is stimulated generating highly compartmentalized cAMP which leads to 
phosphorylation-based activation of the channel (22). In this study they also reported that 
the macromolecular formation is dependent on the phosphorylation status of CFTR as it 
negatively regulates the binding of the CFTR to NHERF1 and also deletion of the R 
domain in CFTR cancelled dose-dependent inhibitory effect of PKA on complex 
formation. In addition, impaired β2-AR-mediated regulation of CFTR function has also 
been recapitulated in NHERF1 deficient mice (49). Also, highly similar proteins 
NHERF2 and PDZK1 failed to compensate for β2-AR-mediated response, indicating that 
complex-mediated regulation of CFTR is NHERF1 specific. It suggests that there is a 
high degree of specificity associated with a compartmentalized response. It is also 
predicted that such compartmentalization based signaling can get compromised in mutant 
and defective CFTR protein.  
 
 
A macromolecular complex of CFTR-NHERF1-NHE3 exists on the luminal surface of 
pancreatic duct 
 
An interesting component of CFTR function is regulation of luminal HCO3
-
 levels. 
CFTR function increases HCO3
-
 secretion when stimulated and reduces HCO3
-
salvaging  
   10 
 
 
 
 
 
Figure 2-2. CFTR and PDZ protein binding partners 
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by other luminal transporters such as Na
+
/H
+ 
exchanger regulatory factor 3 (NHE3) in the 
resting state (51). Later, these two proteins were found to co-exist as a part of a 
macromolecular complex on the apical surface of pancreatic ductal cells. CFTR in this 
complex acutely mediates cAMP-monitored inhibition of NHE3 function and in a chronic  
mechanism elevate expression levels of NHE3 at the plasma membrane (34, 52, 53). 
NHERF1 mediates the functional coupling between CFTR and NHE3 with the first PDZ 
domain of NHERF1 preferentially complexing with CFTR and NHE3 associating with 
the latter half including the second PDZ domain and the C-terminal ERM binding domain 
of NHERF1 (34). With NHERF1as an Ezrin binding protein, regulation of NHE3 by 
PKA would be instantaneous and highly compartmentalized. Interestingly, mutant CFTR 
failed to elicit inhibition of NHE3 function or increase in its expression level, implying 
that an intact CFTR is required for mediating this compartmentalized regulation. Also, 
the macromolecular association possibly has a significant role in stabilizing NHE3 at the 
plasma membrane. This concept runs parallel to the stabilization of CFTR at the plasma 
membrane by NHERF1-mediated coupling of the protein to actin cytoskeleton (54). 
 
 
CFTR is engaged in an inter-domain interaction with Cl
-
/HCO3
-
 exchangers on NHERF 
scaffolds 
 
The mechanism where CFTR can stimulate HCO3
-
 secretion in the activated state 
involves coupling of CFTR with Cl
-
/HCO3
-
 exchangers which include members of the 
SLC26 exchanger family SLC26A3/DRA and SLC26A6/PAT1. SLC26 transporters and 
CFTR assemble together onto NHERF scaffolds (55, 56). Also, an interdomain 
interaction between conserved sulphate transporter and anti-sigma antagonist domain of 
SLC26 transporters at the C-terminal and the R domain of CFTR reciprocally modulates 
activities of these transporters (57). Consequently, stimulation of DRA could increase the 
open probability of CFTR by 6-fold and phosphorylation of the R domain of CFTR 
resulted in an increase in DRA activity. Importantly, NHERF1 and NHERF2 scaffolding 
dynamics within the complex would determine the functional output of this association 
(58). This inter-regulated assembly of SLC26 transporters and CFTR channel functions 
as a HCO3
−
 flux regulating system in the apical membranes of epithelial cells. 
 
 
An LPA2-NHERF2-CFTR macromolecular signaling complex downregulates CFTR 
function in response to LPA 
 
CFTR was also reported to associate with another GPCR lysophosphatidic acid 
receptor-2 (LPA2) bridged by scaffolding protein NHERF2 (42). Supposedly, LPA2 in 
this complex is coupled to Gαi G-protein which inhibits AC function. LPA2 is one of the 
many receptors for lysophosphatidic acid, a physiological phospholipid present in the 
blood (59). Therefore upon stimulation of LPA2 with LPA binding, CFTR activity within 
the complex is downregulated because of the reduced flux of cAMP near CFTR. LPA2 
mediated downregulation of CFTR function conferred protection against cholera toxin 
(CTX)-induced secretory diarrhea in which CFTR has a predominant role (42). An 
interesting component of this study was LPA did not alter the global cAMP levels in the 
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presence of low concentration ADO, implying that the LPA-mediated effect via LPA2 on 
CFTR channel function was highly compartmentalized. Functional consequences of LPA 
on CFTR activity also suggested that diet supplementation with LPA or consumption of 
an LPA-enriched diet can be considered as an alternative therapy for controlling watery 
diarrhea. 
 
 
Spatiotemporal coupling of CFTR and MRP4 at the apical plasma membrane 
 
Another evidence of compartmentalized regulation of CFTR is the association of 
CFTR with the cAMP/cGMP-efflux transporter multi-drug resistance protein 4 (MRP4) 
mediated by PDZK1 (5). Inhibition of MRP4 generates a localized pool of cAMP in the 
vicinity of CFTR allowing spatiotemporal regulation of CFTR channel function in certain 
plasma membrane microdomains. Low dose adenosine in the presence of MRP4 inhibitor 
MK571substantially potentiated CFTR-mediated Cl
-
 currents. However, higher doses of 
ADO (> 20 µM) failed to significantly alter CFTR function in the presence of MK571. 
Mrp4
-/-
 and Mrp4
+/+
 mice with inhibition of MRP4, showed ameliorated CTX-induced 
diarrheal phenotype. MRP4 lines apical and basolateral surfaces of various cell-types and 
its proximity to cyclic-nucleotide effectors would allow the instantaneous modulation of 
their activities as it regulates the flux of cyclic messengers without the need of degrading 
them.  
 
Cyclic nucleotide extrusion by MRP4 represents a mean of maintaining cyclic 
nucleotide balance inside the cell other than degradation by PDEs. 
 
 
CFTR functions as a conductance regulator by coupling physically and functionally with 
renal K channel 
 
The role of CFTR as a conductance regulator other than a Cl
-
 pump was validated 
in its ability to regulate the activity of several transporters in the epithelial membranes. A 
prominent example of such an ability of CFTR is the formation of a macromolecular 
complex of CFTR and renal secretory renal outer medullar potassium (ROMK) channel 
(also known as Kir 1.1 or KCNJ1) at the apical membrane (59). Interestingly, CFTR is 
expressed throughout the nephron. CFTR-ROMK complex would regulate salt absorption 
by controlling K
+
 recycling/secretion across the thick ascending limb of Henle’s loop, 
distal tubule, and collecting duct in the kidney. 
 
 ROMK binds to NHERF scaffolding proteins which is a strong determinant of 
plasmalemmal expression of active ROMK and also coordination of physical and 
functional coupling between CFTR and ROMK. Primarily, this association regulates 
channel sensitivity to sulfonylurea, glibenclamide and intracellular ATP. PKA activity 
acts as a functional switch that determines the CFTR-mediated regulatory effects on 
ROMK. 
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A macromolecular signaling complex of AQP9, NHERF1, and CFTR 
 
CF patients have major fertility issues among both men and women. The major 
cause of CF-males being infertile is the anatomical absence of vas deferens and atrophied 
epididymis at certain regions and, possibly it is the presence of thick and tenacious 
cervical mucus which causes females to be reproductively compromised (60). It has been 
shown that CFTR is not only required to developmentally regulate reproductive systems 
but also for CFTR-mediated regulation of HCO3
-
 secretion in the uterus which is critical 
for the fertilizing capacity of the sperm (60). Fluid content and composition of the male 
reproductive tract is critical to control sperm density and motility. CFTR has a prominent 
role in regulating luminal contents in distal epididymis and vas deferens. Recently, a 
NHERF1-mediated complex of CFTR with another apical protein aquaporin 9 (AQ9) was 
identified in the principal cells of the epididymis and the vas deferens (61). AQ9 belongs 
to a class of transporters which permeates bulk water and neutral solutes such as glycerol 
across the epithelia in response to an osmotic gradient (62, 63). AQ9 lines the apical 
membranes of both ciliated principle cells along the epididymis and vas deferens and 
non-ciliated cells of the efferent ducts fairly co-localizing with CFTR (34). Another study 
demonstrated that CFTR and AQ9 could synergistically modulate luminal fluid 
composition at these regions (64). Since AQ9 could co-immunoprecipate both 
phosphorylated and non-phosphorylated forms of NHERF1, the phosphorylation status of 
NHERF1 would act as a determinant of the regulatory influences of CFTR on AQ9 (61). 
This stems from the fact that phosphorylated NHERF1 causes CFTR to switch from its 
chloride channel activity to a conductance regulator. Similar aspects of regulation hold 
for the CFTR-ROMK protein complex (65). 
 
These studies clearly suggest the potential of CFTR in engaging in multiple-
protein containing signaling complexes which would ensure high fidelity and efficiency 
of CFTR regulation and may also have pathophysiological relevance. 
 
 
Inducible Nitric Oxide Synthase 
 
Inducible nitric oxide synthase (iNOS or NOS2) is a 1153 amino acids long 
protein which is non-constitutively expressed in many cell types and is usually 
upregulated in response to an inflammatory trigger (66). In contrast to other NOS forms 
which include endothelial NOS and neuronal NOS, iNOS does not get regulated by 
intracellular changes in Ca
2+
 (67). Several cell-types such as endothelial cells, 
hepatocytes, enterocytes, immune cells and smooth muscle cells can synthesize iNOS 
(68).  
 
Transcriptional activation of iNOS is under the control of the NFκB pathway 
which gets stimulated in response to cytokines and lipopolysaccharides (LPS). iNOS is a 
modular protein with oxygenase and reductase domains at the N-and C-terminal halves, 
respectively. The oxygenase domain contains the binding site for heme, L-arginine and 
tetrahydrobiopterin (BH4).The reductase domain harbors CaM, NADPH, FAD and FMN 
binding regions. The structure of full-length iNOS is represented in Figure 2-3.  
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Figure 2-3. Representation of structural components of iNOS protein 
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NOS synthesizes NO in a two- step oxidative conversion of L-arginine to NO and 
L-citrulline in the presence of cofactors including heme, FMN, FAD and BH4 and, 
NADPH as an electron donor. Also, iNOS needs to form dimers to be functionally active 
and homodimerization requires binding of L-arginine, heme and BH4 (68). 
 
 
Compartmentalized NO Signaling 
 
Recent data suggests that iNOS activity, although sustained, is subject to 
regulation within mammalian cells and at least 11 different proteins have been reported to 
bind to iNOS (calmodulin, caveolin-1, -2, and -3, NAP110, kalirin, Rac1, Rac2, α-actinin 
4, EBP50 and PDZK1) (69, 70). Besides, some of these interactions can govern the 
subcellular location of the enzyme (69, 70). iNOS harbors the PDZ-domain recognizing 
motif SAL at its carboxyl-terminal and therefore, can tether onto PDZ-scaffolds. iNOS 
binding to EBP50 and CAP-70 are PDZ-mediated interactions and have been shown to be 
critical for polarized expression (at the apical membrane) of iNOS and vectorial NO 
synthesis (69, 70). NO being gaseous in nature is quite a diffusible molecule and, using 
cell culture models, it has been estimated that the diffusion of NO would be in the range 
of several 100 µmeters (71). However, these calculations cannot be applied to complex 
biological systems as NO encounters numerous diffusion barriers inside the cell which 
include interaction with NO-responsive targets, quenching of NO by superoxides to form 
peroxynitrites, the partitioning of NO between polar and apolar media and exposure to 
cholesterol rich biomolecules (71). NO-mediated responses concord with the varied 
clinical stimuli so that the ensuing effects are diverse. This concludes that NO-generated 
responses can be compartmentalized which would involve selective localization of NOSs 
and the proximity of NO-responsive targets (71). Endothelial NOS was found to be 
localized mainly on the golgi apparatus and membrane caveole leading to highly confined 
S-nitrosylation of the target proteins (72). In certain physiological situations, certain 
receptors can stimulate NO synthases. For example, the proinflammatory peptides kinins 
stimulate the synthesis of NO that involves physical interaction of endothelial NOS with 
kinin B1 and B2 receptors (73). Estrogen upon binding to the plasma membrane-
associated estrogen receptors can excessively stimulate NO generation from eNOS (74). 
Exclusive expression of iNOS on the apical membranes of the polarized epithelial cells 
suggests that the luminal membrane would be more enriched with NO and NO-dependent 
signaling pathways.  
 
The most notable NO-mediated effect inside the cell is the stimulation of the 
cGMP synthesizing enzyme soluble guanylate cyclase (sGC) (75). NO binds to the 
attached prosthetic heme group present in sGC and induces conformational changes that 
stimulate the enzyme activities. In this fashion, NO can also regulate the amounts of 
cGMP inside the cell. It is also known that NO can stimulate different subtype of sGCs 
generating compartmental cGMP which regulates distinct receptors in the neuronal cells 
to regulate long-term potentiation and neurotransmitter release critical for synaptic 
plasticity (76). Also, if NO can be compartmentalized, it would also lead to localized 
cGMP generation which can be potentially important in conditions like IBD which has 
remarkably increased levels of iNOS. cGMP is an important cellular messenger and can 
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regulate fluid homeostasis across the epithelial cells lining small intestine and colon (77). 
cGMP can stimulate CFTR Cl
- 
channel function through kinase (PKA or PKG)-mediated 
phosphorylation of the channel (77). The membrane-bound cGMP-dependent protein 
kinase (cGK) type II which is predominantly expressed in intestinal epithelial cells co-
localizes with CFTR and phosphorylates the channel to regulate its activity (78). Whether 
microdomain cGMP generated as a consequence of NO-cGMP pathway would play a 
role in CFTR regulation has not been elucidated before. 
 
 
Role of CFTR in Health and Disease 
 
 
Cystic fibrosis 
 
CFTR was identified as a gene mutated in the pernicious autosomal recessive 
genetic disorder cystic fibrosis (CF). CF is most prevalent among Caucasians and one in 
every 3500 babies in USA would have CF. It is estimated that around 75,000 people in 
the world suffer from CF. CF patients suffer from severe exocrine insufficiency causing 
an obstructed mucosa especially in the lung airways. Sticky and thick mucus accumulates 
in the lung which favors colonization of opportunistic bacteria including Pseudomonas 
aeruginosa, Burkholderia cepacia, Staphylococcus aureus and Haemophilus influenza 
(35). P. aeruginosa forms biofilms composed of macrocolonies which are resistant to 
anti-microbial agents. Also, inflammatory responses get triggered accompanied by 
reduced levels of anti-inflammatory cytokines and proteases. The chronic infectious 
condition of the lung with the persistent deterioration of lung function becomes the major 
cause of morbidity and mortality of CF patients. Other complications associated with CF 
include fibrotic pancreas, pancreatic insufficiency, potentially fatal condition of the gut 
(meconium ileus) in about 10% of the patients and male infertility. The best biomarker of 
CF with a correlated involvement of CFTR in the disease is Cl
-
. Therefore, in order to 
confirm if a patient has CF, salt concentration in the sweat less than 60mmol/L is 
considered as intermediate- or non-CF. This is based on the hypothesis that CFTR in 
sweat glands absorb Cl
-
. In case of a defective CFTR as in CF, Cl
-
 fails to be absorbed 
properly and therefore, forms salt. In the cases where the sweat Cl
-
 is normal or 
intermediary but the individual has CF-manifestations or bears a family history of CF, it 
is necessary  to confirm the possibility of having CF by measuring nasal potential 
difference (NPD) (79). In CF, luminal surfaces have more negative charge either because 
of the overly active Na
+
 absorption in the absence of CFTR or the inability to absorb Cl
-
. 
Usually, the basal PD of CF patients is approximately two-to three-folds higher than 
normal individuals (80)  
 
There are around 1900 CFTR mutations known today but not every mutation 
leads to CF (81). Any CFTR mutation which results in defective protein synthesis, halted 
processing, defective trafficking, block in regulation, altered conductance or reduced 
synthesis of CFTR can cause CF (82). F508Del mutation in CFTR is the most common 
CF-causing mutation accounting for about 70% of the CF-underlying defects. F508Del 
mutation causes CFTR to be misfolded and recognized by ER-associated degradative 
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machinery. Now other defects associated with F508Del have been recognized which 
include altered conductance, mislocalization, impaired post-ER trafficking, poor sub-
apical membrane retrieval, markedly low-stability at the membrane and decreased mRNA 
levels (83). Newly recognized defects with F508Del-CFTR include thermal 
destabilization caused by this mutation and the impaired inter-domain interactions 
between NBD1 and membrane spanning domains (84-86). 
 
Because F508Del-CFTR is known to possess partial Cl
-
 conductance once it 
reaches the cell surface, several CF therapies have been based on the potentiation of a 
small population of F508Del-CFTR present at the cell surface. The CF-potentiator VX-
770 is clinically approved for CF-patients carrying G551D-CFTR (exhibits a locked Cl
-
 
conductance) and its efficacy is being evaluated in F508Del homozygous mutant CF-
patients (87). Other therapies have focused on lifting the processing defects to increase 
F508Del-CFTR number at the plasma membrane. However, the clinical trial of CF-
corrector VX-809 which increases the F508Del-CFTR population reaching at the surface 
failed to show promising lung improvement in CF-patients although sweat Cl
-
 
concentration was reduced with VX-809 treatment (88).  
 
Interestingly, it is not only the deficiency of CFTR which leads to a pathological 
condition as CFTR might contribute to the enlargement of renal cysts in individuals with 
polycystic kidney disease  and hyperactivity of CFTR in the gut causes infectious 
diarrhea (89, 90).  
 
 
Role of CFTR in fluid secretion and diarrhea 
 
Approximately eight liters of fluid is secreted into the intestine everyday (77). 
Regulation of fluid secretion is critical as enzymes and solutes need aqueous media to 
diffuse and function and, also the mucosa needs to be lubricated for preventing frictional 
damage during motility (77). The key to fluid secretion is how several electrolyte 
transporters present on the gut epithelia are regulated. Secretion of selective electrolytes 
and solutes into the lumen sets the osmotic gradient for the movement of water. It was 
mostly believed that water takes the paracellular route, however recent evidences indicate 
the possibility of transcellular water transport. There is a simple mechanics, very well- 
understood today, on how epithelial ion transporters function on the intestinal surface to 
regulate water movement. 
 
It is now accepted that together with Na
+
 absorption, Cl
-
 secretion constitutes the 
predominant driving component of fluid secretion (77). The electroneutral transporter 
Na/K/2Cl (NKCC) on the basolateral membrane takes up Cl
-
 into the cell which sets the 
electrochemical potential for Cl
-
. When the Cl
-
 channels on the apical surface, 
(predominantly CFTR) open, Cl
-
 gets transported into the lumen. Na
+ 
K
+
-ATPase located 
on the basolateral surface functions as an electrogenic transporter to maintain the thrust 
for Cl
-
 secretion out of the cell. In order to maintain electroneutrality, Na
+
 is secreted into 
the lumen via a paracellular pathway resulting in an osmotic flux of water.  The 
schematics of the entire process are shown in Figure 2-4. 
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Figure 2-4. Fluid transport model in a polarized intestinal epithelial cell 
 
Concerted actions of various transporters located on the apical and basolateral 
membranes of polarized gut epithelial cells regulate fluid transport. 
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It is a well-known fact now that secretory and absorptive processes along the 
length of the intestine are highly asymmetric to the extent that the surface operating  
mechanisms will be different than those in the intestinal crypts (77). Still, relevance of 
CFTR-mediated Cl
-
 secretion in regulation of fluid homeostasis is irrespective of the 
region of the gut and cannot be discounted. In CF, the failure to secrete sufficient Cl
-
 
leads to dehydrated and obstructed mucosa (meconium ileus) in 10% of the neonates, 
distal intestinal obstruction syndrome (DIOS), and chronic constipation in older CF 
patients (91).  
 
Secretory diarrhea is a consequence of major electrolyte transport abnormalities in 
the gut mucosa. Colonization by certain pathogenic enterobacteria majorly E. coli, Vibrio 
cholerae, Yersinia enterocolitica, Shigella flexneri, and Salmonella typhimurium and 
their toxic secretagouges lead to secretory diarrhea (34). Given the fact that increase in 
intracellular levels of cAMP, cGMP or Ca
2+
 activates CFTR Cl
- 
channel function, any 
molecular agent which causes unregulated increase in the levels of these messengers 
would surpass the regulatory threshold on CFTR and cause fluid dysregulation such as 
diarrhea. CFTR heterozygosity conferred resistance to diarrhea induced by CTX, an 
enterotoxin from Vibrio cholera, which underscored the direct involvement of CFTR in 
causing secretory diarrhea (90). In this study, CF-mice failed to have any secretory 
phenotype in response to CTX challenge. The underlying mechanism of CTX-induced 
diarrhea is irreversible ADP-ribosylation of G-protein Gαs by CTX
 
which locks it in the 
active GTP-bound state. Constitutively active Gαs stimulates AC in an unregulated 
manner which pools the cell with cAMP. Excessive cAMP causes overstimulation of 
CFTR activity and downregulation of Na
+
 absorption culminating into excessive flow of 
water into the gut and diarrhea. A question of interest would be whether these 
enterotoxins can be used as a therapy for CF patients to partially relieve meconium ileus? 
Enterotoxins will be effective in CF patients with the condition of meconium ileus 
provided they are able to stimulate CFTR-independent secretions. It is also known that 
cholera toxin cannot trigger any secretion in CF mice. It is to be noted that predisposition 
to meconium ileus is genetically determined and the predisposition of the CF patients to 
this phenotype is variable. Also, not all CF patients have meconium ileus implying that 
several other genomic loci than CFTR are also involved. A recent study reports that 
guanlyl cyclase 2C encoded by GUCY2C can be a likely modifier of meconium ileus 
associated with CF (92). Therefore, if the genes other than CFTR can be targeted that 
improves secretion, there is a possibility that meconium ileus can be effectively 
controlled.  
 
Heat-stable enterotoxins from E. coli or Y. enterocolitica directly stimulate 
membrane-bound guanylyl cyclase C (GC-C) and enhance intracellular cGMP (93). 
CFTR activity gets stimulated by the efficient phosphorylation of the channel by 
membrane localized cGMP-dependent protein kinase II (cGKII) which in combination 
with hypoabsorption of Na
+
 result in diarrhea (94, 95). Also, upregulated levels of iNOS 
and prostaglandin generating enzyme cyclooxygenase-2 could enhance Cl
-
 secretion and 
leakiness of epithelial junctions in a colon epithelial cell line challenged with 
enteroinvasive bacteria (96). This can be the possible mechanism of infectious diarrhea 
caused by these bacteria. 
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Approximately 2.5 million children in the developing world die annually from 
infectious diarrhea and it accounts for 21% of the causes of death of children aged under 
5 years (97). Interestingly, infectious diarrhea comes next to cardiovascular disorders as a 
major cause of mortality especially in the subsets of pediatric and elderly population. 
With the validation of CFTR involvement in many forms of secretory diarrhea, therapies 
to control diarrhea are now focused on developing drugs to block CFTR Cl
-
 secretion in 
the patients some of which are already known to be effective. The plant latex derivative 
SP-303 was demonstrated to attenuate CTX-induced CFTR-dependent secretion in vitro 
and its naturally occurring counterpart, derived from the latex of the plant Croton lechleri 
has always been in use by natives of South America to control various kinds of watery 
diarrheas. Based on the effects of LPA in downregulating CFTR function and 
ameliorating diarrheal phenotype of CTX-injected mice, an LPA-rich diet can effectively 
control certain forms of diarrhea. Cesinex®, a tannic acid based medical food is 
prescribed for diarrheal episodes in USA and could successfully attenuate CTX-induced 
diarrhea in mice (98). It is known that egg albumen has high amounts of LPA. Based on 
the aforementioned studies, a formulation combining tannic acid and egg albumen can 
exhibit improved anti-diarrheal properties. Also, MRP4 which couples closely with 
CFTR and regulates its function in physiological and pathophysiological situations can 
represent another target for therapeutic interventions of diarrheal disorders. 
 
With a major contribution of CFTR in regulation of fluid secretion across the gut 
mucosa, there is an imperative interest in the contribution of CFTR in other diarrheal 
disorders including, inflammatory bowel disorders, irritable bowel disorders and 
diverticulitis. However, the exact role of CFTR in contributing to diarrhea in these 
disorders has not been clearly elucidated. This aspect would define the role of CFTR 
under a pathological situation. 
 
 
Inflammatory Bowel Disease 
 
Inflammatory bowel disorders (IBD) represent chronic relapsing inflammatory 
condition of the gastrointestinal tract (GI) and are broadly categorized into ulcerative 
colitis (UC) and Crohn’s disease (CD). UC extends proximally from the rectum and is 
restricted to the colon mucosa while CD is transmural and can affect any part of the GI 
tract (99). IBD patients suffer from diarrhea, abdominal pain, and weight loss and with 
long persistence are predisposed to an increased risk of developing colorectal cancer 
(100). More than one million people world-wide suffer from IBD and it is also the major 
cause of morbidity in the western world. The etiology of IBD is understood to be 
multifactorial and the precise onset of IBD is still not established (101). In particular, a 
compromised epithelial barrier in the intestine of genetically predisposed IBD patients 
supposedly cause commensal intestinal flora to trigger innate inflammatory response, 
thus leading to the disease. Therefore, IBD is often described as an autoimmune disorder.  
 
Diarrhea is the most common and distressing symptom in IBD patients often 
‘bloody’ with a 50% consistency in acute flare-ups of CD and almost 100% of UC 
patients (102). IBD patients have varied diarrheal manifestations leading to an unresolved 
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conclusion about the mechanism of diarrhea in IBD. It is critical to define the precise 
pathophysiologic mechanisms of diarrhea in IBD patients to effectively control it. 
 
 
Electrolyte transport abnormalities in IBD  
 
It is an accepted fact that IBD patients have disturbed electrolyte transport. 
Inflammatory secretagogues present in the supernatant of inflamed human colonic 
mucosa could stimulate electrogenic Cl
-
 secretion in rat colonic mucosa in Ussing 
chambers which suggested that Cl
- 
secretion is probably altered in IBD (103). However, it 
did not reconcile with the observed diminished intrinsic responsiveness of the mucosa to 
the secretory stimuli and loss of the lumen-negative potential difference (PD) (103, 104). 
There were reports on the reduced cAMP-mediated secretory response of the inflamed 
mucosal tissue which may not necessarily have to do with the defects in the cAMP 
pathway or cAMP-responsive proteins but with the type of cAMP-elevating ligands or 
the receptor profile of the ligands used (103). Alterations in the expression and function 
of CFTR in IBD have not been determined with reproducibility (103). Genetically, it has 
been determined that the carriers of the loss-of-function mutation of CFTR, F508Del are 
8-times less likely to develop IBD (105). However, conclusive data on the phenotypic 
role of Cl
-
 secretion and CFTR in IBD-associated electrolyte abnormalities is lacking. 
CFTR-function is the rate-limiting determinant of luminal fluid levels also considering 
the fact that it regulates the function of several other transporters and channels including 
Na
+
/H
+
 exchangers, anion exchangers, sodium-bicarbonate transporters, K
+
 channels, 
epithelial sodium channel (ENaC), ATP-release channels, gap-junctional channels and 
aquaporins (47, 106). The regulation mostly happens in the form of large macromolecular 
signaling complexes of CFTR. Therefore, it is critical to precisely define the role of 
CFTR in IBD-associated diarrhea and if macromolecular complexes of CFTR would play 
a role in it.  
 
 
iNOS in inflammatory bowel disease 
 
Pertaining to the blatant inflammatory profile of IBD, the therapeutic approaches 
for IBD have been mostly based on targeting inflammatory mediators. iNOS which has 
been found to be elevated in IBD mucosa has also been studied as a therapeutic target in 
animal models of experimental colitis. Colonic mucosa of IBD patients have two to five-
fold higher amounts of NO compared to those in the controls or in the mucosa of 
remitting UC patients. This correlates with the increased expression and activity of iNOS 
(107, 108).  The correlation between iNOS activity and disease activity has been less 
consistent for CD (109). iNOS has also been linked to UC disease susceptibility in the 
Spanish population subset (110). iNOS in contrast to other NOS isoforms causes 
sustained NO production in the µmolar range (75). Excessive NO inside the cell causes 
oxidative stress (by forming peroxynitrites-ONOO
-
) and may also lead to the formation 
of potential carcinogens (75, 111, 112). Oxidative stress has been shown to substantially 
lead to mucosal injury that compromises the barrier integrity rendering it leaky. 
Excessive NO/ONOO
-
 activity has been demonstrated to cause cytoskeletal nitration and 
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oxidation in the intestinal mucosa from IBD patients (113). The toxic megacolon, a 
potentially lethal manifestation of UC, has also been associated with the presence of large 
amounts of iNOS in the colonic muscularis propria and it was also reported that 
administration of iNOS inhibitor L-NAME helped patients recover from megacolon (75, 
114). The drug named mesalamine given to the IBD patients can scavenge peroxynitrites 
generated as a consequence of sustained iNOS activity and can attenuate apoptosis (75).  
 
 
Animal models of inflammatory bowel disorders 
 
Inflammatory bowel disease has a complicated etiology and more than 60 animal 
models are available to study IBD. These IBD models have provided significant 
contributions in dissecting out various mechanisms contributing to the development of 
the disease and further channel it into therapeutic interventions of IBD. IBD mouse 
models have been primarily classified into gene knockout (KO) models, transgenic 
models, chemically-induced colitis models and adoptive cell transfer models (115). 
Induction of intestinal inflammation in mice by chemical irritation is one of the most 
commonly used approach because it is simple, inexpensive, and less time-consuming and 
the onset, duration, and severity of the inflammation can be easily controlled (116). The 
dextran sulphate sodium (DSS) and trinitrobenzene sulfonic acid (TNBS) induced colitis 
are the most popular animal models of chemically-induced mucosal inflammation (116). 
Several studies have validated the evaluations of DSS-induced colitis model to be 
extended to translational studies of human. This model gives the flexibility of inducing 
acute, chronic, or relapsing conditions of colitis by changing the concentration and 
duration of administration of DSS (116). DSS is a sulfated polysaccharide permeable to 
mucosa and causes epithelial injury (116). Animals are fed continuously with 2–5% DSS 
in the drinking water for short period (4–9 days) in order to induce acute colitis and the 
symptoms usually appear from the 4
th
 day onwards (117). It is considerably important to 
take into account the molecular weight of DSS to be used as it governs the severity, 
extent, localization of colitis and also colitis-induced dysplastic lesions (116). Clinical 
manifestations of acute DSS colitis closely mimic IBD-like symptoms and include weight 
loss, diarrhea, rectal bleeding; however, in many cases animals eventually die (75, 116, 
117). Typical histopathology of acute DSS-colitis is characterized by mucosal damage, 
cryptitis, crypt abscesses and neutrophil infiltration of lamina propria (116, 117). As the 
DSS colitis gets chronic, the inflammatory profile becomes less representative of IBD 
and partially loses histopathological features of large bowel in IBD (116). Based on the 
numerous advantages that DSS colitis model offers and the close resemblance it bears to 
IBD, the model can prove invaluable in order to study the epithelial ion transport 
abnormalities in colitis and the contribution of selective channels in causing diarrhea. 
 
TNBS is dissolved in ethanol and the ethanol enema causes disruption of the 
mucosal barrier and the TNBS chemical penetrates into virtually all layers of the intestine. 
Consequently, granuloma infiltrates can be observed transmural. The colitis seen in this 
model is a Th type-1 response which mimics a CD background (115). 
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Specific Aims 
 
The unifying hypothesis of my study is that excessive amounts of inducible nitric 
oxide synthase (iNOS) are expressed at the apical plasma membrane of the gut epithelia 
in inflammatory bowel disease where iNOS physically and functionally couples with 
cystic fibrosis transmembrane conductance regulator (CFTR; a cGMP-activated Cl
-
 
channel) and potentiates its Cl
-
 channel function through stimulation of NO-cGMP 
pathway. Schematics of the hypothesis are shown in Figure 2-5. 
 
The specific aims of the study were to answer the following questions: 
 
 Is iNOS overexpressed and does it exhibit highly polarized expression in the gut 
epithelial cells of IBD-affected tissue? 
 
 Is iNOS involved in a high affinity interaction with PDZ-protein NHERF2 at the 
apical plasma membrane of pathophysiological relevance? 
 
 Does NHERF2 bridge CFTR and iNOS in a form of macromolecular signaling 
complex? 
 
 Does iNOS contribute to microdomain cGMP at the plasma membrane via the 
potentiation of the NO-cGMP pathway? 
 
 Does iNOS-induced compartmentalized cGMP potentiate CFTR Cl- channel 
function at the plasma membrane in IBD? 
 
 Does inhibition of CFTR and iNOS activities confer resistance to colitis-
associated diarrhea? 
 
 Does compromise of the macromolecular complex among CFTR, NHERF2 and 
iNOS ameliorate diarrhea in colitis models? Is diarrhea attenuated in DSS and 
TNBS colitis models in a Nherf2 
-/-
 genetic background? 
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Figure 2-5. Model of the hypothesis 
 
The molecular machinery of how a macromolecular complex of CFTR and iNOS 
contributes to diarrhea in inflammatory bowel disease. 
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CHAPTER 3.    METHODS 
 
 
Reagents 
 
Zaprinast was purchased from Enzo Life Sciences (Farmingdale, NY), and DSP 
was obtained from Pierce (Thermo Fisher, Rockford, IL). Bacterial LPS was purchased 
from Sigma-Aldrich (St. Louis, MO), and recombinant human TNF-α, IL-1β, and IFN-γ 
were obtained from BD Biosciences (Franklin Lakes, NJ). Dextran sodium sulfate (DSS; 
MW 36,000-50,000) was purchased from MP Biomedicals (Irvine, CA). 
 
 
Cell Culture and Transfections 
 
HEK-293 and HT29-CL19A cells were cultured in DMEM-F12 and DMEM high 
glucose media, respectively (Invitrogen, Carlsbad, CA) containing 10% serum and 1% 
penicillin/streptomycin and maintained in a 5% CO2 incubator at 37
o
C. Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) was used to express various plasmids in HEK-293 cell 
lines according to the manufacturer’s instructions. Stable cell lines were generated by 
lentiviral transfection and selected with puromycin (2 µg/ml). 
 
 
Purification of Flag- and HA-iNOS, and GST-His-S-and His-S-iNOS-C-tail Proteins  
 
HEK-293 cells stably expressing hemagglutinin (HA)-iNOS were plated on 100 
mm dishes, and grown till 100% confluency. The cells were then washed with PBS twice 
and lysed with PBS containing 0.2% Triton-X-100 and protease inhibitor cocktail 
(phenylmethylsulfonyl fluoride 1 mM, pepstatin-A 1 μg/ml, leupeptin 1 μg/ml, aprotinin 
1 μg/ml). The cell lysate was mixed on a shaker for 10 min at 4°C and centrifuged for 10 
min at 13,000 rpm. The supernatant containing total protein was immunoprecipitated 
using α-Flag or α-HA beads overnight. The beads with bound protein were washed and 
the protein was eluted with 100 mM glycine (pH 2.2) and quickly neutralized with 150 
mM tris (pH 8.8). The eluted protein was subjected to SDS-PAGE on 4-15% gel (Bio-
Rad, Hercules, CA) and transferred to PVDF membrane and either visualized with Gel 
Code Blue or immunoblotted with α-Flag-HRP or α-HA-HRP antibody.  
 
For the purification of GST-His-S- or His-S-tagged iNOS-C-tail, pET-41- and 
pTriEx-4-iNOS-C-tail constructs were used to transform BL21 and Origami competent 
cells, respectively. Bacterial cultures (1L) were grown and the protein synthesis was 
induced with IPTG (0.2 mM) for 4 h. For GST-tagged and His-tagged proteins lysis 
buffer comprising of 50 mM Tris, 1 mM EDTA and 10% Sucrose pH7.2 and 
resuspension buffer containing 25 mM HEPES-KOH, 400 mM KCl and 5 mM β-
mercaptoethanol (added fresh) respectively, was used followed by addition of lysozyme 
(1mg/ml) prepared in lysis or resuspension buffer for 30 min at 4°C. Next, 2.1% Triton-
X-100 was added to the lysate and mixed for another 30 min at 4°C. Lysate was 
transferred to clean centrifuge tubes and spun at 15,000 rpm for 30 min at 4°C. To the 
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clear supernatant 100 µl of Glutathione beads (Thermo Scientific, Waltham, MA) or 
Talon-beads (Clontech, Mountain View, CA) were added as appropriate and mixed for 2-
3 h at 4°C. Glutathione beads and Talon beads containing proteins were washed three-
four times with PBS 0.2% Triton-X-100 and resuspension buffer; respectively in the 
presence of protease inhibitors. GST-His-S-iNOS-C-tail and His-S-iNOS-C-tail proteins 
were eluted with 20 mM glutathione and 200 mM imidazole, respectively for 1-4 times. 
Protein concentrations of the samples were quantified using Bradford assay or by direct 
absorbance at 280 nm. 
 
 
PDZ-array 
 
Purified GST-NHERF1/NHERF2/PDZK1 PDZ proteins were immobilized on 
nitrocellulose membrane in various concentrations using a slot blot applicator. Purified 
GST-His-S-iNOS-C-tail (100 ng) protein was added to the membrane in 0.1% Tween 20, 
2% BSA with protease inhibitors for overnight binding at 4°C. Next day, the membrane 
was washed extensively with TBS 0.1% Tween-20 and probed with S-HRP antibody. 
 
 
Pull-down Assay 
 
HEK-293 cells overexpressing HA-iNOS were lysed in lysis buffer (PBS 0.2% 
Triton X-100 + protease inhibitors). Cell lysates were mixed for 15 min followed by 
centrifugation at 15,000 g for 10 min at 4°C. GST-NHERF2 was added and mixed at 4°C 
with the clear supernatant for 30-60 min. Glutathione beads (20 μl) were then added and 
mixed overnight at 4°C. Thereafter, the mixtures were spun at 3000 rpm for 2 min, and 
the beads were washed three times with the same lysis buffer before the proteins were 
eluted from the beads with the sample buffer (containing 2.5% β-mercaptoethanol). 
Eluates were separated on 4-15% gel and immunoblotted with mouse monoclonal α-
iNOS antibody (BD Biosciences, Franklin Lakes, NJ). 
 
In the next set of assays, HEK-293 cells overexpressing iNOS and iNOS-∆PDZ or 
mucosal scrapings from DSS-treated and untreated colons were lysed in lysis buffer (PBS 
containing 0.2% Triton X-100 and  protease inhibitors), mixed for 15 min followed by 
centrifugation at 15,000 rpm for 10 min at 4°C. GST-NHERF2 was added and mixed at 
4°C with the clear supernatant (~ 500 µg) for 30-60 min. Glutathione beads (20 μl) were 
then added and mixed overnight. Thereafter, the mixtures were spun at 3000 rpm for 2 
min, and the beads were washed three times with the same lysis buffer before the proteins 
were eluted from the beads with the sample buffer (containing 2.5% β-mercaptoethanol). 
For the tissue pull-down, proteins were eluted with100 mM glycine (pH 2.2) and quickly 
neutralized with 150 mM Tris (pH 8.8). Eluates were separated on 4-15% gel and 
immunoblotted with mouse monoclonal α-iNOS antibody and rabbit polyclonal 1314 
CFTR antibody. 
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Co-immunoprecipitation  
 
HA-iNOS-HEK-293 and control-HEK-293 cells were incubated with the cross-
linker dithiobis succinimidyl propionate (DSP, 1 mM) for 10 min at 37°C. Cells were 
then lysed using lysis buffer-1X PBS, containing 0.2% Triton-X-100 and protease 
inhibitors and the clear supernatant was subjected to immunoprecipitation by using HA- 
beads (Sigma-Aldrich, St.Louis, MO) for overnight at 4°C. The cross-linked complex 
was eluted with 100 mM glycine (pH 2.2) and quickly neutralized with 150 mM Tris (pH 
8.8). The eluted proteins were mixed with the sample buffer (5X; containing 1% β-
mercaptoethanol), denatured, subjected to SDS-PAGE, transferred to PVDF membrane, 
and immunoblotted using rabbit polyclonal α-NHERF2 antibody. 
 
 
Direct Sensitized Fluorescence Resonance Energy Transfer Microscopy and Data 
Analysis 
 
For direct sensitized emission FRET, HEK-293 cells were transiently transfected 
with pECFP-iNOS, YFP-CFTR, Yellow-NHERF2, pCMV-HA-NHERF2 either singly or 
in combination using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Single transfected 
cells were used to acquire CFP- or YFP- only images for bleedthrough calculations. The 
cells were maintained at low density (20-40% confluence) on a cover slip bottom dish 
(MatTek; Ashland, MA), washed twice with warm HBSS and 2 ml of HBSS was added. 
Cells were imaged in a dark room at 37°C. Corrected FRET was calculated on a pixel-by-
pixel basis for the entire image by using equation: FRETc = FRET - (0.5 × CFP) - (0.06 × 
YFP), where FRET, CFP, and YFP correspond to background-subtracted images of cells 
co-expressing CFP-iNOS and YFP-CFTR/Yellow-NHERF2 acquired through the FRET, 
CFP, and YFP channels, respectively. The factors 0.5 and 0.06 are the fractions of bleed-
through of CFP and YFP fluorescence, respectively, through the FRET filter channel. 
The corrected FRET (FRETc) was normalized with donor CFP intensity (FRETc/CFP), 
yielding the normalized corrected FRET (N-FRETc), and the intensity of N-FRETc 
images was presented in monochrome mode, stretched between the low and high 
renormalization values, according to an intensity to color mapped lookup table with black 
indicating low values and white indicating high values. All calculations were performed 
using the Channel Math and FRET modules of the SlideBook 4.2 software (Intelligent 
Imaging Innovations; Denver, CO).  
 
 
AlphaScreen™ Assay for iNOS-NHERF2 Interaction 
 
We used AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) 
to study the interaction between purified full-length GST-NHERF2 and biotin-iNOS-C-
tail peptide (last 10 amino acids), using AlphaScreen™ GST Detection Kit (PerkinElmer, 
Waltham, MA). In brief, starting from 300 µM concentration, biotin-iNOS-C-tail peptide 
was serially diluted (in 1/2 log dilution series) in assay buffer [1x HEPES, 0.1% BSA, 
0.05% Tween 20 (v/v), pH 7.2] containing GST-NHERF2 (100 nM final concentration). 
For the interaction between His-S-iNOS-C-tail and GST-NHERF2, similar procedure was 
   28 
followed with the starting concentration of 100 nM for His-S-iNOS-C-tail with 
progressive dilution and 100 nM final concentration for GST-NHERF2. The resulting 
solutions were incubated at room temperature for 30 min. Each sample solution (15 μl) 
was transferred to a white opaque 384-well microplate (OptiPlateTM-384; PerkinElmer, 
Waltham, MA) in triplicates and into which anti-GST acceptor beads (5 μl, 20 μg/ml 
final concentration) were added and incubated for 30 min at room temperature. 
Streptavidin donor beads (5 μL; 20 μg/ml final concentration) were then added and 
incubated for 2 h at room temperature. Anti-GST acceptor beads (5 μl, 20 μg/ml final 
concentration) and Nickel chelate donor beads (5 μl, 20 μg/ml final concentration) were 
used for GST-His-S-iNOS-C-tail and GST-NHERF2 interaction. The plate was read on 
FLUOstar-Omega plate reader (Ortenberg, Germany).  
 
The specificity of the observed AlphaScreen™ binding signals between biotin–
iNOS-C-tail peptide and GST–NHERF2 protein was verified by AlphaScreen™ 
competition assay. The assay procedure is similar to the association assay described 
above except that a non-biotinylated iNOS peptide was serially diluted in the assay buffer 
starting with 1 mM final concentration and mixed with GST–NHERF2 (100 nM final 
concentration). 
 
 
Macromolecular Complex Assembly 
 
GST-His-S-iNOS-C terminal 112 a.a. fusion protein (20 μg) was mixed with 
various amounts of GST-NHERF2 (0-20 μg) at 4°C for 1 h, followed by mixing with 
Sepharose beads (20 μl) for another 1 hr. This step, which is called pairwise binding, was 
done in 200 μl of lysis buffer (1X PBS-0.2% Triton X-100 + protease inhibitors). The 
complex was washed twice with the same buffer and allowed to incubate overnight with 
0.5 μg purified Flag-CFTR at 4°C with constant mixing. The complex was washed 
extensively with lysis buffer, eluted with sample buffer, and immunoblotted with Flag-
HRP antibody. 
 
 
DSS-induced Colitis Murine Model 
 
C57BL/6 male mice, 7-8 weeks old, were fed with 5% DSS in drinking water for 
7 days and euthanized later. The control mice were fed with autoclaved water.  
 
In order to evaluate the contribution of CFTR in DSS-induced diarrhea, CFTR 
inhibitor CFTRinh-172 (150 µg/kg) prepared in saline was administered intraperitoneally 
on the 5
th
 day of DSS-treatment following appearance of symptoms of colitis and was 
given twice per day for 3 days. On the 8
th
 day mice were sacrificed and colon tissue was 
removed and assessed for total length, rectal bleeding score using ColonScreen-ES 
(Helena laboratories, Beaumont, TX), wet/dry weight ratio and histological examination. 
Dry to wet weight ratio was calculated by drying fecal pellets from the colon at 50°C 
overnight. 
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iNOS inhibitor L-NIL (N6-(1-Iminoethyl)-L-lysine dihydrochloride) (Cayman 
Chemical, Ann Arbor, MI) known to be highly selective for iNOS was administered 
intraperitoneally at a concentration of 10mg/kg/12 h for 6, 4 and 2 days in three different 
mouse groups treated with 5% DSS containing four animals per group. Saline was 
administered in the control animals. 
 
 
TNBS Colitis Murine Model 
 
TNBS colitis was induced by a single rectal injection of 3.75 mg of TNBS 
dissolved in 50% ethanol-PBS solution into the descending colon of C57BL/6 male 
Nherf2 
-/- 
and Nherf2 
+/+
 mice using a catheter inserted up to 3-4cm into the anus. The 
volume of TNBS enema was kept at 100 µl. The mice were anesthetized with 
intraperitoneal injection of xylazine-ketamine solution (50 mg/kg). The animals were 
observed for 3 days with regular weight measurements, and afterwards euthanized for 
further assessment. 
 
 
Determination of Clinical Scores 
 
Stool consistency and the presence of occult blood were determined on day 7 of 
DSS treatment. Stool consistency for TNBS-colitis was determined on day 3. Briefly, 
stool scores were determined on the scale of 0 to 5 depending upon the looseness of the 
fecal matter with, 0 = well-formed pellets that did not stick to the anus, 1= semi-formed 
stools that did not stick to the anus, 2-4= depending upon the fluidity of the fecal matter 
that did not stick to the anus and 5= non-standing liquid stool. Bleeding scores were 
determined as follows: 0 = no blood, 1 = positive hemoccult, 2-4 = based on significance 
of visible blood traces in the stool, 5 = gross rectal bleeding.  
 
 
Histopathology Scoring for DSS Colitis 
 
After day 7, the entire colon was excised to measure the length of the colon. 
Colons were washed, fixed in formalin and embedded in paraffin. Tissue sections were 
stained with hematoxylin & eosin (H&E). Histology was scored by a pathologist in a 
blinded fashion based on combination of inflammatory cell infiltration (score 0–3) and 
tissue damage (score 0–3) as described previously (118). The presence of occasional 
inflammatory cells in the lamina propria was scored as 0, increased numbers of 
inflammatory cells in the lamina propria was assigned score 1, confluence of 
inflammatory cells extending into the submucosa was scored as 2, and transmural 
extension of the infiltrate was scored as 3. For tissue damage, no mucosal damage was 
scored as 0, lymphoepithelial lesions were scored as 1, surface mucosal erosion or focal 
ulceration was scored as 2, and extensive mucosal damage and extension into deeper 
structures of the bowel wall was scored as 3. The combined histological score ranged 
from 0 (no changes) to 6 (extensive infiltration and tissue damage). 
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Human Colon Sections 
 
We used 5-micron thick sections of normal and IBD-affected, paraffin-embedded 
human gut tissues. These slides were made available by the Tissue Service Core, 
Pathology Department (University of Tennessee Health Science Center) under the IRB-
approved protocol 05-03854-XM. These samples and preexisting tissue from normal and 
IBD individuals were de-identified.  
 
 
Human mRNA Expression Data Set 
 
The mRNA expression data set was downloaded from the NCBI Gene Expression 
Omnibus  database (accession number GSE1710) (119). This data set contains 31 
samples generated from 10 patients with CD, 10 patients with UC, and 11 normal 
controls. Data sets were log-transformed and then normalized by Zipf's law. The 
normalized mRNA expression values of iNOS, CFTR, and NHERF2 were extracted from 
the data set.  
 
 
Immunohistochemistry 
 
Paraffin-embedded human and mouse colon sections were stained for iNOS as 
follows. Certain colon sections from mouse were embedded in a swiss-roll configuration 
for better visualization. Slides were deparaffinized in xylene three times, 5 min each, 
followed by dehydration with ethanol. Antigen retrieval was done with Borg DeCloaker 
RTU (Biocare Medical, Concord, CA) in a pressure cooker for 5-10 min. Slides were 
cooled for 5 min, and tissues were permeabilized with 0.2% Triton-X-100 in PBS for 10 
min. Tissues were then blocked in 2.5% horse serum for 2 h or overnight. Slides were 
rinsed with 1X PBS and incubated with rabbit polyclonal iNOS (abcam, Cambridge, UK 
; 1:100 to 1:150), rabbit polyclonal R3194 CFTR(1:100) and rabbit monoclonal NHERF2 
(Cell signaling, Danvers, MA; 1:50) antibodies at 4°C overnight. Slides were incubated 
with peroxidazed 1 (Biocare Medical, Concord, CA) to block endogenous peroxidase 
activity for 5 min. Biotin-conjugated rabbit horseradish peroxidase antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) was used in 1:100 dilution for 30 min, and 
Vectastain ABC reagent (Vector labs, Burlingame, CA) was used for signal amplification 
for another 30 min. Slides were developed with 3-3’-diaminobenzidine solution (Biocare 
Medical, Concord, CA) according to the manufacturer’s instructions. For histological 
examination, slides were lightly stained with hematoxylin and eosin. For 
immunofluorescence, polarized HT29-CL19A cells were fixed in 4% formaldehyde and 
permeabilized with 0.2% Triton-X-100 in PBS for 10 min. Cells were blocked in 5% 
BSA in PBS for 2 h and incubated with rabbit polyclonal R3194 CFTR (1:100) and 
mouse monoclonal iNOS (BD Biosciences, Franklin Lakes, NJ; 1:100 primary 
antibodies) at 4°C overnight. Rabbit Alexa-fluor-488 and mouse Alexa-fluor-568 
(Invitrogen, Carlsbad, CA) were used (1:100), cells were mounted, and images were 
taken with a Carl Zeiss confocal microscope (Thornwood, NY). The images were 
analyzed with ImageJ software (NIH; http://rsb.info.nih.gov/ij/). 
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Total Internal Reflection Fluorescence Microscopy 
 
Human colon tissue slides were immunostained for iNOS using rabbit polyclonal 
iNOS primary antibody from abcam and rabbit Alexa-fluor-488 secondary antibody. 
TIRF images were taken using inverted Olympus microscope with a 100X oil objective. 
Antibody coupled dye was excited at 488 nm and images of emitted fluorescence were 
captured at a resolution of 128 x 128 pixels (1 pixel = 0.33 µm) with EM-CCD camera. 
 
 
Proximity Ligation Assay 
 
Paraffin-embedded human colon sections were used for performing proximity 
ligation assay  (Olink Bioscience, Uppsala, Sweden). Briefly, human colon sections were 
deparaffinized and incubated with mouse monoclonal iNOS (BD Biosciences; 1:100) and 
rabbit monoclonal NHERF2 (Cell Signaling; 1:50) primary antibodies at 4°C overnight. 
Next day, PLA was performed with anti-rabbit (plus) and anti-mouse (minus) Duo link In 
Situ PLA probes on the tissue slides following manufacturer’s instructions. Next day, 
images were taken using Zeiss LSM-5 Pascal confocal microscope. 
 
 
Measurement of CFTR-mediated I
-
 Influx Using a YFP-based Halide Sensor 
 
HEK-293 cells with different protein expression profiles were co-transfected with 
pCDNA3-TM-Cl sensor. After 24 h, the transfected cells were seeded in 12-24-well 
plates and cultured for another 24 h. The cells were washed twice with 200 µl 136 mM 
NaNO3 solution per well prepared in the wash buffer containing 137 mM NaCl, 4.5 mM 
KH2PO4, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 5 mM HEPES, pH 7.2 and 100 µl 
of the same buffer was added to each well. Fluorescence readings were recorded at 37 °C 
on a FLUOstar-Omega (BMG Labtech; Ortenberg, Germany) microplate reader equipped 
with HQ500/20X (500 ± 10 nm) excitation and HQ535/30M (535 ± 15 nm) emission 
filters and two syringe pumps. Intracellular YFP fluorescence was monitored 
continuously for 90-150 intervals 1 second each for each well. At 5 s after the start of 
fluorescence recording, 100 µl of an influx buffer (272 mM NaI in the wash buffer) 
containing 250 µM zaprinast was added to activate CFTR-mediated I
-
 influx. 
 
 
Iodide Efflux Assay 
 
CFTR-mediated halide efflux was measured using an iodide efflux assay. For the 
induction of iNOS levels, the following cytokine composition (cytomix) was used: TNF-
α 10U/ml, IFN-γ 200U/ml, LPS 1µg/ml, IL-1β 1µg/ml. HT29-CL19A cells grown on 60 
mm dishes were incubated with the cytomix for 48 h. HT29-CL19A cells, which were not 
treated or treated with the cytomix, were subjected to iodide efflux assay as previously 
described (4). Briefly, cells were loaded for 60 min at room temperature with loading 
buffer (136 mM NaI prepared in the buffer with the following composition: 137 mM 
NaCl, 4.5 mM KH2PO4, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 5 mM HEPES, pH 
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7.2). Extracellular NaI was washed away thoroughly (5-7 times) with efflux buffer (136 
mM NaNO3 prepared in the buffer as mentioned before replacing 136 mM NaI in the 
loading buffer) and then, cells were equilibrated for 1 min each for four times to establish 
a stable base line in efflux buffer alone. After establishing basal equilibrium with the 
nitrate buffer, cells were treated with 1mM L-Arginine for 15 min followed by zaprinast 
(500 µM) to activate CFTR function.  The iodide concentration of each aliquot collected 
at 1 min interval was determined using an iodide-sensitive electrode (Thermo Scientific, 
Waltham, MA) and converted to iodide content (nanomoles/min).  
 
 
Short-circuit Current Measurements 
 
Polarized colon epithelial cell (HT-29CL19A) monolayers were grown on Costar 
Transwell permeable supports (Cambridge, MA; filter diameter 6.5 mm) until the 
monolayers reached confluency and a resistance of ~1500 ohms. HT-29CL19A cells 
were pretreated with or without the cytomix with the composition as mentioned before 
for 48 h and the transwells were mounted in an Ussing chamber. Short-circuit currents 
were measured as described previously (5). Epithelial cells were bathed in Ringer’s 
solution (mM) (Basolateral side: 140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44 KH2PO4, 1.3 
CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 10 glucose, pH 7.2, [Cl
-
] = 149), and low Cl
-
 
Ringer’s solution (mM) (Apical side: 133.3 Na-gluconate, 5 K-gluconate, 2.5 NaCl, 0.36 
K2HPO4, 0.44 KH2PO4, 5.7 CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 10 mannitol, pH 
7.2, [Cl
-
] = 14.8) at 37°C, and saturated with 95% O2 and 5% CO2.  A 2 mV pulse was 
applied every 1 min throughout the experiment to check for the integrity of the epithelia. 
After stabilization of basal Isc Cells were treated with 1mM L-Arginine for 15 min 
followed by adding zaprinast (100-500 μM) to the basolateral side. CFTRinh-172 (20-50 
μM) was added to the apical side at the end of the experiment to verify that the short-
circuit currents were CFTR-dependent. 
 
 
Ratiometric Fluorescence Resonance Energy Transfer Microscopy and Data 
Analysis 
 
For ratiometric FRET, HEK-293 cells were grown on glass-bottom dishes 
(MatTek, Ashland, MA) and transfected with pcDNA3-empty vector,  pcDNA3-iNOS, 
and pcDNA3-m-cygnet 2.1 using Lipofectamine 2000. Cells were washed twice with 
Hank’s balanced salt solution (HBSS) and mounted on an inverted Olympus wide-field 
microscope (IX51, U-Plan Fluorite 60x 1.25 NA oil-immersion objective) for FRET 
imaging. The stage was maintained at 37°C constantly, and the cells were maintained in 
the dark in HBSS. After establishing the baseline, zaprinast was added as indicated. 
Ratiometric FRET imaging was performed as described previously (5). Time-lapse 
images were obtained with 1x1 binning, 100-300 ms exposure time and 1 min intervals. 
Images were acquired using an EM CCD camera (Hamamatsu) mounted on an Olympus 
IX51. The light source used was 300W xenon lamp with a neutral density filter. A JP4 
CFP/YFP filter set was used for image capture (Chroma, Brattleboro, VT) which includes 
a 430/25 nm excitation filter, a double dichroic beam splitter and two emission filters 
   33 
(470/30 nm for CFP and 535/30 nm for FRET emission) alternated by filter-change 
controller Lambda 10-3 (Sutter instruments, Novato, CA). Slidebook 4.2 software was 
used for data analysis. Following background subtraction, multiple regions of interest 
(10-20) were selected (3-5 cells) for data analysis using ratio module. The emission ratio 
(CFP/FRET) was obtained from CFP and FRET emission of background subtracted cells. 
 
 
Co-immunoprecipitation in Colon Tissue 
 
To immunoprecipitate CFTR and NHERF2 from DSS-treated mouse colon, rabbit 
polyclonal iNOS antibody (1µg) was mixed with 20 µl protein A/G agarose for 1 h at 
4°C. Rabbit polyclonal non-immune IgG (1µg) was used as control. Bound IgG was 
washed once with 1ml 0.1M N-ethyl morpholin (NEM; pH 7.5) buffer. The IgG is cross 
linked to protein A/G agarose using 10mM Dimethyl pimelimidate (DMP; Pierce Chem. 
Co. Dallas, TX) in NEM buffer for 30 min at 22°C. The cross-linking reaction is stopped 
by washing the beads once with 100mM Tris-base (pH 8.0). The cross-lined beads were 
incubated with the lysate (1mg) in 1x PBS, containing 0.2% Triton X-100 overnight at 
4°C. Next day, proteins were eluted using glycine buffer pH 2.2. Proteins were subjected 
to SDS-PAGE and probed with the respective antibodies. 
 
 
Real-time PCR 
 
Total mRNA was isolated from HT-29CL19A cells (untreated or pretreated with 
cytomix) using RNeasy kit from Qiagen (Hilden, Germany). The RNA was treated with 
DNase I at 37°C for 1 h, and the concentration of each sample was measured using 
NanoDrop (Thermo Scientific, Waltham, MA). DNA-free RNA (1 µg) was converted to 
cDNA by using Transcriptor first-strand cDNA synthesis kit (Roche, Basel, SUI) 
according to the manufacturer’s instructions. Real-time PCR reaction was performed 
using TaqMan® probe based method in the LightCycler 480 instrument (Roche, Basel, 
SUI). Probes and primers were designed using universal probe library (Roche). The target 
genes were normalized with the TBP gene (probe 3). The following probes and left and 
right primers were used for real-time PCR amplification of each of the genes: 
 
iNOS (probe 37) 
 
Left: ACCAGTACGTTTGGCAATGG 
Right: TCAGCATGAAGAGCGATTTCT 
 
CFTR (probe 8) 
 
Left: CACAGCAACTCAAACAACTGG 
Right: TGTAACAAGATGAGTGAAAATT 
 
NHERF2 (probe 24) 
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Left: TCCGAAGCTGGCAAGAAG 
Right: ATAGCCCTGAGGTCCCTTTC 
 
 
cGMP Assay 
 
Mice colons were quickly frozen in liquid nitrogen and ground to a fine powder. 
Tissue was dissolved in 600 µl of 6% trichloroacetic acid (TCA) and spun at 10,000 rpm 
at 4°C. Pellet was lysed in lysis buffer (Tris-Cl EDTA containing 0.5% Triton-X-100 and 
0.1% SDS) and the supernatant was used for protein quantitation and further processing. 
Supernatant was then transferred to a glass vial and washed three times with water 
saturated ether (1:1) with water forming the top phase. Sample of interest exists in the 
water phase and is taken out from the top after each wash. Residual ether was removed 
by boiling the samples briefly at 68°C. Samples were used for cGMP measurement by 
direct cGMP ELISA from Enzo Life Sciences (Farmingdale, NY) as per manufacturer’s 
directions. A cGMP standard provided in the kit was run in parallel for the quantitation of 
cGMP in the samples. 
 
 
NO Assay 
 
Colon tissue was homogenized in 1ml of 1X PBS 0.2% Triton-X-100 buffer and 
protein concentration of the supernatant was determined. 100 µl of the tissue supernatant 
was mixed with equal volume of Griess reagent and incubated for 20 min. Plate was read 
at 540 nm and the nitrite levels were determined using a sodium nitrite standard curve. 
Nitrite levels were normalized with the total protein concentration. 
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CHAPTER 4.    RESULTS 
 
 
Purification of Full-length and Truncated iNOS Proteins 
 
In this part of the study, affinity epitope-tagged full-length iNOS proteins 
involving Flag and HA tags at the N-terminal were first cloned into pcDNA3 vector. 
These constructs were primarily used for protein purification, performing biochemical 
protein-protein interaction assays like pull-down assays and co-immunoprecipitation. 
Also, Flag- and HA-iNOS were cloned into pLenti destination vector. pLenti-Flag- and 
HA-iNOS were later used for making stable cell lines after initial selection on 6 µg/ml 
puromycin for 1 week till only positive cells survived and later, trypsinized and 
maintained on 2 µg/ml puromycin containing DMEM F-12 media. Five to six 100 mm 
dishes of cells expressing Flag- or HA-iNOS were maintained till complete confluence. 
The cells were then washed with 1 XPBS twice and lysed with PBS containing 0.2% 
Triton-X-100 and protease inhibitor cocktail. The cell lysate was mixed on a shaker for 
10 min at 4°C and centrifuged for 10 min at 13,000 rpm. The supernatant containing total 
protein was immunoprecipitated using α-Flag, α-HA beads overnight. The beads with 
bound protein were washed and the protein was eluted with 100 mM glycine (pH 2.2) and 
quickly neutralized with 150 mM tris (pH 8.8). The eluted protein was subjected to SDS-
PAGE on 4-15% gel (Bio-Rad, Hercules, CA) and visualized with Gel Code Blue. A 
coomassie gel with HA-iNOS is shown in Figure 4-1.  
 
 iNOS-C-tail (1041-1153 amino acids) retaining the PDZ-motif was cloned into 
pET-41- and pTriEx-4 vectors to generate GST-His-S-iNOS-C-tail and His-S-iNOS-C-
tail, respectively. The idea of generating this construct was increased options of affinity 
tags, ease of purification with a smaller construct and performing biochemical assays. 
GST stands for Glutathione-S-Transferase protein (26 KDa) which is a commonly used 
epitope tag for protein purification and exhibits high affinity for glutathione agarose 
Proteins were induced in an E.coli bacterial system using IPTG and retrieved after 
bacterial lysis using suitable lysis buffers as described in Chapter 3 Methods. The GST-
fusion and His-tagged proteins were purified using affinity chromatography involving 
glutathione beads and talon beads, respectively. Talon beads are precharged with Co
2+ 
with a unique tetradentate metal chelator and exhibit high specificity for His-tagged 
proteins. For the GST-tagged protein elution was done using 10 mM glutathione in PBS 
(pH 7.4). His-S-iNOS-C-tail protein was eluted in 200 mM Imidazole prepared in 
resuspension buffer (described in Chapter 3 Methods). Glutathione and imidazole act 
competitive to GST and Histidine residues binding to the respective resins facilitating the 
elution of the proteins. The eluted proteins were further purified using size exclusion 
chromatography. Purified GST-His-S-iNOS-C-tail and His-S-iNOS-C-tail are shown in 
Figures 4-2A and 4-2B respectively, on a coomassie stained gel. The protein smear 
appearing below the major band in Figure 4-2B represents partial degradation of the 
protein. 
 
Alternatively, fluorescent CFP-tagged iNOS and Yellow (a variant of YFP)-
tagged NHERF2 constructs were obtained or cloned to perform protein-protein  
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Figure 4-1. Purification of HA-iNOS 
 
Coomassie stained gel showing purified full-length HA-iNOS (~ 130 KDa) from HA-
iNOS overexpressing HEK-293 cells. 
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Figure 4-2. Purification of truncated iNOS proteins 
 
Coomassie stained gel showing purified (A) His-S-iNOS-C-tail and (B) GST-His-S-
iNOS-C-tail (1041-1153 amino acids) expressed in E.coli. 
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interaction studies in live cells using FRET. Yellow tag was preferred over YFP because 
of its improved spectral properties and better signal. HEK-293 cells were the ideal choice 
to perform protein-protein interaction studies and make stable cell lines because they 
originate from human, are easy to transfect, and respond to various agonists.  
 
 
iNOS Exhibits High Affinity Interaction with NHERF2 
 
Given that iNOS harbors a putative PDZ motif to bind to PDZ-domain containing 
scaffolding proteins, we first screened the interaction of iNOS with different PDZ 
proteins to identify the high-affinity interactions of iNOS. An array of GST-tagged PDZ 
proteins (NHERF1, NHERF2, and PDZK1) referred to as a PDZ array was generated. A 
PDZ array comprises of proteins immobilized on nitrocellulose membrane using a slot 
blot applicator. It allows screening of preferential protein-protein interactions and the 
relative binding affinities of various PDZ-proteins towards a specific protein at the same 
time. In the mentioned experiment, the immobilized PDZ-proteins were screened for 
binding to GST-His-S-iNOS-C-tail (100 ng) in buffer comprised of 0.1% Tween-20 and 
2% BSA in PBS in an overnight binding at 4°C. Our results demonstrated that NHERF2 
showed the highest binding affinity towards iNOS, whereas NHERF1 showed a weak 
binding and PDZK1 did not bind to iNOS (Figure 4-3A). A similar assay is referred to as 
a dot-blot assay where protein samples are dropped on to a nitrocellulose membrane in a 
volume of 1-2 µl using a pipette on a self-drawn grid and allowed to dry. His-tagged 
protein His-S-MAST205 was used as a positive control for the assay. The second 
interacting protein GST-His-S-iNOS-C-tail (100 ng) is added to the membrane in 3-5 ml 
of 0.1% Tween-20 and 2% BSA in PBS and binding is performed overnight at 4°C. Next 
day the membrane is washed six times with 0.1% Tween-20 in TBS and probed with S-
HRP antibody (1:5000) at room temperature for 1 h. The membrane is again washed 
extensively with 0.1% Tween-20 in TBS six times for five min each. The membrane is 
developed with ECL™ chemiluminescence solution. The data is shown in Figure 4-3B. 
 
Given the fact that iNOS is not normally expressed under native conditions, HEK-
293 cells were transiently transfected with full-length pcDNA3-iNOS (1 µg) using 
Lipofectamine 2000. Cells are subsequently lysed in 0.2% Triton-X-100 buffer in PBS. 
The rationale behind using Triton-X-100 based lysis buffer is that Triton-X-100 is a non-
ionic detergent which does not interfere with protein-protein interactions, After the lysis, 
lysate enriched in proteins is subjected to a pull-down assay with GST-NHERF2. The 
rationale of this experiment is to elucidate interaction of NHERF2 with full-length iNOS. 
In this assay, GST-NHERF2 (0-15 µg) is allowed to mix with the HEK-293 iNOS 
overexpressing cell lysate for 1 h. GST-NHERF2 interacting protein complexes are then 
immobilized on glutathione beads overnight. Next day, beads are washed to remove 
unbound and non-specific proteins and the protein complexes are eluted in 5X laemmli 
buffer containing 5% β-mercaptoethanol, subjected to SDS-PAGE and western blot. The 
blot was probed with a mouse monoclonal against iNOS. A concentration-dependent 
interaction was observed between iNOS and GST-NHERF2 (Figure 4-4). Co-
immunoprecipitation and immunoblotting were also used to detect the interaction 
between full-length iNOS and NHERF2 in an overexpression condition. These  
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Figure 4-3. iNOS preferentially binds NHERF2 among NHERF proteins 
 
An immunoblot showing GST-tagged PDZ proteins immobilized on nitrocellulose 
membrane in (A) a slot-blot (B) dot-blot format probed with S-HRP for detecting 
interaction with His-S-iNOS-C-tail.   
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Figure 4-4. NHERF2 immunoprecipitates full-length iNOS from the cells 
 
An immunoblot for full-length iNOS, overexpressed in HEK-293 cells 
immunoprecipitated with GST-NHERF2. 
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procedures are based on the principle of immunoprecipitation which in co-
immunoprecipitation principally involves capturing native interactions in the cells using 
antibodies conjugated to resins. We generated a stable HA-iNOS (and Flag-iNOS) 
overexpressing HEK-293 cell line using a lentiviral expression based system and the full 
length purified protein is shown in Figure 4-1. Certain protein-protein interactions can be 
quite transient and unstable and can disappear in stressful lysis and wash steps. For 
transient interactions, proteins can be covalently cross-linked using a cross-linker, which 
would help prevent loss of binding partners. NHERF2 interaction with iNOS could not be 
detected as such and required cross-linker. We used DSP for cross-linking the proteins. A 
temperature condition of 37°C and preciseness of time is very critical for successful 
cross-linking. DSP (10mM) was added to the cells in pre-warmed PBS with Ca
2+
 (100 
µM) and Mg
2+
 (1 mM) and incubated for 10 min at 37°C followed by lysis in cold PBS 
0.2% Triton-X-100 buffer. HA beads (100 µl) were added to immunoprecipitate the 
complex. The next day, samples were eluted using glycine buffer and western blot was 
performed and probed with rabbit polyclonal NHERF2 antibody. We detected that 
NHERF2 co-immunoprecipitated with iNOS upon cross-linking the complex (Figure 
4-5). 
 
Next, using direct sensitized FRET, we investigated whether the interaction could 
be detected in live cells. FRET is a procedure to detect protein-protein interactions in live 
cells involving a radiationless mode of energy transfer from one chromophore referred to 
as donor to second chromophore referred to as acceptor that exists within a diameter of 
100 nm of the donor. HEK-293 cells were co-transfected with CFP-iNOS (donor) and 
Yellow-NHERF2 (acceptor) to measure normalized corrected FRET value (N-FRETc). 
The FRET is being mentioned as corrected as the bleed-through values deriving from 
acceptor excitation in the absence of donor with the donor excitation wavelength have 
been accounted for in the final measurement. Using the FRET module of SlideBook 4.2 
software, an approximate FRETc value of 35 ± 4% N- was estimated at the plasma 
membrane in cells that co-expressed CFP-iNOS and Yellow-NHERF2 (Figure 4-6A). 
The control group comprised of HEK-293 cells co-expressing CFP-iNOS donor with 
Yellow-fluorophore acceptor. Little or no FRET signal was observed in the controls 
(Figure 4-6B).  
 
The specificity of PDZ-dependent iNOS-NHERF2 interaction was further 
investigated using a highly sensitive amplified luminescent proximity homogenous assay 
(AlphaScreen
TM
). The assay is referred as homogenous as no washing steps are involved 
in the process. Also, AlphaScreen
TM
 can detect very low affinity interactions in the 
picomolar range. The fundamental requirement of an AlphaScreen
TM
 readout is the 
proximity of excited donor and acceptor beads within 200 nm. Donor and acceptor beads 
are conjugated with affinity molecules that can be matched with the epitopes on target 
proteins. Donor beads contain a photosensitizer, phthalocyanine, which when excited at 
680 nm generates an excited and a reactive form of O2, singlet oxygen. Singlet oxygen 
would transfer energy to thioxene derivatives within the acceptor bead if present in the 
right proximity of the donor bead leading to an emission of 520-620 nm wavelength 
which is quantified as counts per second (cps) in a microplate reader. The usual readout 
of a pair-wise protein-protein interaction with AlphaScreen
TM
 is in the form of a bell-  
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Figure 4-5. iNOS and NHERF2 exist within a protein complex in the cells 
 
Western-blot data to depict co-immunoprecipitated NHERF2 and HA-iNOS in HEK-293 
cells using a cross-linker DSP and probed with rabbit NHERF2 polyclonal antibody. 
 
  
   43 
 
 
 
 
 
Figure 4-6. iNOS and NHERF2 protein complex exists at the plasma membrane 
in the cells 
 
(A) Representative pseudocolor images showing the expression of CFP-iNOS and 
Yellow-NHERF2 in HEK-293 cells. The intensity of direct sensitized FRET (N-FRETc) 
between CFP-iNOS and Yellow-NHERF2 at the plasma membrane was shown in a 
monochrome mode, according to a temperature-based look-up table (n=3 independent 
experiments). (B) Representative pseudocolor images showing the expression of CFP-
iNOS and Yellow-fluorophore in HEK-293 cells. N-FRETc in the co-transfected cells 
was shown in pseudocolor and monochrome modes. 
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shaped curve termed as Hook-effect. Hook-effect is the common read-out profile of 
saturable bimolecular detection systems including FRET and AlphaScreen
TM
. Standard 
curves obtained with AlphaScreen
TM
 are characterized by a titratable increase in signal 
until it attains a maximal value termed as hook point. After the hook point signal begins 
to drop as excessive concentrations of target molecules oversaturates the donor and the 
acceptor beads and restricts their association. The interaction between GST-NHERF2 
(100 nM) and GST-His-S-iNOS-C-tail (30 nM to 300 µM) or Biotin-iNOS-C-tail peptide 
(last 10 amino acids; QPSSLEMSAL; 30 nM to 300 µM) was studied using 
AlphaScreen
TM
. GST (100 nM) was used as a control in these experiments. A micromolar 
range interaction was observed for GST-His-S-iNOS-C-tail and biotin-iNOS peptide with 
GST-NHERF2, while no interaction was observed in the GST control (Figures 4-7A and 
4-7B). The specificity of the interaction was demonstrated by the competition-based 
assay between biotin-iNOS and iNOS peptides for interaction with GST-NHERF2. The 
interaction between GST-NHERF2 and biotin-iNOS peptide was disrupted in a 
concentration-dependent manner by the untagged iNOS peptide, while DMSO did not 
disrupt the interaction (Figure 4-8). 
 
Taken together, our data demonstrate that iNOS exhibits a high-affinity 
interaction with NHERF2. PDZ proteins have been shown to mediate the localization of 
various proteins at or near the plasma membrane, thereby enabling cell polarization to 
mediate vectorial functions (120). Given that, NHERF2 binds to PDZ-domain proteins 
predominantly associating with the plasma membrane and there is high amount of FRET 
signals between iNOS and NHERF2 at the plasma membrane, we reasoned that iNOS-
NHERF2 interaction may play an important role in mediating apical localization of iNOS 
and in coupling it with other apical membrane-bound proteins. Towards this end HEK-
293 cells with a knockdown of NHERF2 were generated and about 50% knockdown was 
achieved with these cells compared to HEK-293 cells with scrambled siRNA (Figure 
4-9). These cells were immunostained for overexpressed iNOS to demonstrate the role of 
NHERF2 in regulating sub-cellular localization of iNOS. HEK-293 cells with scrambled 
siRNA exhibited higher sub-apical membrane localization compared to NHERF2 
knockdown cells (Figure 4-10). In order to demonstrate the relevance to colon epithelial 
cells, human colon epithelial cell line HT29-CL19A were transfected with iNOS and 
iNOS-∆PDZ, with the latter lacking the ability to bind NHERF2 (Figure 4-11). First, 
HEK-293 cells were transfected with iNOS and iNOS-∆PDZ and lysed, and a pull-down 
was performed with GST-NHERF2 immobilized on glutathione beads in a similar 
manner as described above. Interaction of iNOS with GST-NHERF2 served as positive 
control for the experiment. Based on this data, HT-29CL19A cells were immunostained 
for iNOS and it could be demonstrated that removal of PDZ-motif reduced sub-apical 
localization of iNOS (Figure 4-12). This data implies that iNOS-NHERF2 interaction has 
pathological relevance. 
 
 
NHERF2 Bridges CFTR and iNOS into a Macromolecular Signaling Complex 
 
Given that (i) iNOS binds with high affinity to NHERF2 and localizes primarily 
at the membrane (108); and CFTR interacts with NHERF2 with high affinity (42), we  
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Figure 4-7. GST-NHERF2 and iNOS protein fragments interaction using 
AlphaScreen™ assay  
 
AlphaScreen™ assay to determine the binding affinity between (A) biotin-iNOS-C-tail 
peptide and GST-NHERF2 and (B) His-S-iNOS-C-tail and GST-NHERF2 (n=3 
samples). 
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Figure 4-8. AlphaScreen™ competition assay for GST-NHERF2 and iNOS-C-tail 
peptide 
 
AlphaScreen™ competition assay shows that a non-biotinylated iNOS peptide competes 
against biotin iNOS peptide for binding to GST-NHERF2 protein, verifying the 
specificity of the interaction (n=3 samples). 
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Figure 4-9. NHERF2 knockdown in HEK-293 cells 
 
Western blot to demonstrate NHERF2 knockdown in HEK-293 cells using lentiviral 
siRNA particles. Bar-graph to quantitate around 50% knockdown of NHERF2 compared 
to scrambled siRNA. β-actin was used for protein normalization. 
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Figure 4-10. Role of NHERF2 in determining iNOS localization inside the cell 
 
iNOS immunostaining in HEK-293 cells with no iNOS expression and without NHERF2 
knockdown (upper panel), with iNOS expression and without NHERF2 knockdown 
(middle panel) and with iNOS expression and NHERF2 knockdown (bottom panel). 
HEK-293 cells with no NHERF2 knockdown represent cells transduced with scrambled 
siRNA.  
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Figure 4-11. PDZ-interaction based iNOS-NHERF2 coupling 
 
Western blot depicting pull-down of full-length iNOS and iNOS-∆PDZ with GST-
NHERF2. Removal of PDZ motif disabled interaction of iNOS with NHERF2. 
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Figure 4-12. PDZ-interaction dependence of iNOS localization in colon epithelial 
cells 
 
iNOS immunostaining in HT-29CL19A cells with no iNOS expression (left panel), with 
iNOS expression (middle panel) and with iNOS-∆PDZ expression (right panel). 
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rationalized that a macromolecular complex might exist among CFTR, NHERF2, and 
iNOS with NHERF2 serving as the scaffolding protein. Abilities of NHERF proteins to  
assemble macromolecular complexes of CFTR of functional relevance have been shown 
previously and described in detail in Chapter 2. A plausible explanation of NHERFs as 
preferred scaffolds for CFTR is their predominant sub-apical localizations in polarized 
epithelial cells (120). Also, NHERFs can anchor enzymatic and regulatory proteins and 
therefore act as conduits of regulatory influences on CFTR channel activity (22, 30, 34, 
121). It is to be noted that NHERF scaffolds are not limited to CFTR and have been 
shown to assemble many signal-transduction complexes at the plasma membrane which 
immensely profile vectorial physiology (122). Nonetheless, NHERF mediated complexes 
of CFTR have been shown to be central to fluid regulation and its ability to function as 
conductance regulator. To test whether a complex of CFTR-NHERF2-iNOS exists, we 
performed an in vitro macromolecular formation assay with purified GST-His-S-iNOS C-
tail, GST-NHERF2, and Flag-CFTR proteins. Briefly, His-S-iNOS C-tail (20 µg) and 
GST-NHERF2 at two different concentrations (5 and 15 µg) are mixed first for 1 h and 
immobilized on S-beads (20 µl). Purified Flag-CFTR is then added to the protein-bead 
mix and allowed to interact overnight at 4°C. An assembled protein complex 
immobilized on S-beads is shown in Figure 4-13 (upper panel). A macromolecular 
complex of CFTR and iNOS could be inferred from the data shown in Figure 4-13 
(lower panel).We found that the complex could only be assembled when NHERF2 was 
present, and that the formation of this complex increased in a NHERF2-dependent 
manner Figure 4-13 (lower panel). It correlates with the fact that stoichiometry of CFTR 
and NHERF scaffold determines the efficiency of CFTR macromolecular assemblies.We 
proceeded to determine NHERF2 mediated CFTR-iNOS interaction using PLA in HEK-
293 cells. Briefly, iNOS and Flag-CFTR were overexpressed in HEK-293 cells with and 
without NHERF2 knockdown. The knockdown process did not impair the ability of the 
cells to overexpress proteins and equal levels of iNOS and Flag-CFTR proteins were 
detected in scrambled and NHERF2 knockdown cells. NHERF2 knockdown reduced the 
amounts of PLA signals in iNOS and Flag-CFTR co-transfected cells by 50% (Figure 
4-14). As mentioned and demonstrated before that tempering with the CFTR and 
NHERF2 stoichiometry affects CFTR macromolecular assemblies and plausibly control 
the dynamics of interaction. We used direct sensitized FRET to test if iNOS and CFTR 
interaction can be altered by controlling the concentration of NHERF2 in live cells. 
Toward this end, HEK-293 cells were co-transfected with CFP-iNOS and YFP-CFTR 
and subjected to FRET imaging. N-FRETc signal between CFP-iNOS and YFP-CFTR at 
the plasma membrane was very weak but could be visualized on a small temperature-
based FRET look up scale (Figure 4-15A). Increasing the expression of NHERF2 by 
transfecting the cells with different amounts of pCMV-HA-NHERF2 cDNA (0, 0.2, 0.5, 
0.75 and 1 µg), enhanced the N-FRETc signals by 2- to 2.5-fold compared to the HA-
NHERF2 untransfected cells (Figure 4-15B). Only selective data is presented here to 
emphasize the concept. Concomitantly, with the presence of greater amounts of 
NHERF2, there will be more iNOS getting trafficked to the plasma membrane and the 
possibility of achieving macromolecular associations with CFTR would be higher. 
Transfection with more than 1 µg of HA-NHERF2 could not further increase the FRET 
signal, implying that the complex was already saturated. 
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Figure 4-13. CFTR-NHERF2-iNOS macromolecular complex 
 
A pictorial representation of the macromolecular complex assay (upper panel). A 
macromolecular complex (MMC) was detected in vitro with three purified proteins (His-
S-iNOS-C-tail, GST-NHERF2, and Flag-CFTR) (lower panel).  
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Figure 4-14. Knockdown of NHERF2 expression compromises CFTR-iNOS 
physical coupling at the plasma membrane 
 
Representative images of the PLA assay in HEK-293 cells with scrambled and NHERF2 
knockdown transfected with pcDNA3-empty vector (left, indicated by symbol φ), Flag-
CFTR and iNOS both (middle and right). PLA signal was quantified as fluorescence 
intensity and represented in the form of a bar-graph (lower panel). Data represent the 
mean ± SEM (n=8-49 regions of interest); *****P < 0.00001 as determined using 
student’s t-test.  
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Figure 4-15. Modulating iNOS-CFTR interaction at the plasma membrane 
 
(A) Representative direct sensitized FRET depicting interaction between CFTR and 
iNOS at the plasma membrane in HEK-293 cells. The cells were single or cotransfected 
with CFP-iNOS and YFP-CFTR, and the pseudocolor images show the expression. HA-
NHERF2 was also included in the transfection media to increase N-FRETc. N-FRETc 
between CFP-iNOS and YFP-CFTR at the plasma membrane was shown in a 
monochrome mode, according to a temperature-based look-up table.  
(B) Bar graph represents the increase in N-FRETc between CFTR and iNOS with 
increasing concentrations of HA-NHERF2. Data represent the mean ± SEM (n=3 
independent experiments, 8-10 regions of interest per experiment); ****P < 0.00001 as 
determined using student’s t-test.  
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iNOS Protein Is Organized into Clusters at or near the Apical Plasma Membrane in 
Inflammatory Bowel Disorders  
 
iNOS levels have been shown to be upregulated in colonic biopsies from IBD 
patients in UC and CD, and enhanced NOS levels and associated disease manifestations 
are better correlated in UC patients than in Crohn’s colitis patients (75). Inflammation 
patterns in UC vs. CD appear superficially similar but are distinct. Inflammation in CD 
can be found in any part of the gastrointestinal tract and usually occurs in the forms of 
patches and extends beyond the mucosa into deeper layers of the gut. In UC, 
inflammation extends proximally from the rectum and is restricted to the colon, usually 
occurs in a continuum and affects the mucosal surface only (99). Due to better correlation 
between iNOS function and pattern of inflammation in UC, the current study focuses on 
UC. Costello et al. (2005) used human endoscopic biopsies from sigmoid colons of 
normal individuals and patients suffering from active CD and UC to examine the  pattern 
of genome-wide gene expression in IBD (123). The sample size comprised a total of 31 
individuals with the data from normal (n=11), CD (n = 10) and UC patients (n = 10) to be 
included for the analysis. The transcripts were datamined corresponding to iNOS, 
NHERF2, and CFTR in active UC-affected biopsies and were compared with those in the 
normal control samples. The rationale behind including CFTR in the analysis is based on 
three facts. First, IBD patients have severe diarrhea and CFTR function is directly 
correlated with the development of diarrhea. Whether CFTR contributes to diarrhea in 
IBD is not known. Second, we have demonstrated that iNOS binds NHERF2 and 
previously, several studies have described interactions between CFTR and NHERF 
proteins. Therefore, it becomes reasonable to explore the possibility of iNOS and CFTR 
being connected to NHERF2. Third, iNOS can be functionally coupled to CFTR chloride 
channel function as iNOS can stimulate cGMP production via the canonical NO-cGMP 
pathway and it is already known that cGMP can potentiate CFTR activity. We 
determined that iNOS expression level was 2-fold higher in UC patients compared to the 
normal controls (Figure 4-16). The change in CFTR expression levels was not 
significantly altered, and NHERF2 expression slightly increased in UC patients compared 
to the normal individuals (Figure 4-16). This correlates with the prevailing data on iNOS 
activity in IBD-affected patients which is increased by 2-3 fold and also, with the 
determined expression changes in CFTR in IBD which have been not quite consistent. 
Change in expression of NHERF2 in IBD-affected tissue has not been determined 
previously and our current analysis demonstrates that NHERF2 levels are not 
significantly altered in IBD.  
 
Histological staining of normal and UC-affected human colon tissues showed 
disrupted mucosal architecture and massive infiltration by the immune cells (Figure 
4-17). Using immunohistochemical analysis, we confirmed the increase in iNOS levels 
and its predominant localization at or near the apical plasma membrane in UC-affected 
colon compared to normal colon (marked arrows in upper panel; Figure 4-18). NHERF2 
was found to localize predominantly at or near the apical plasma membrane in both 
normal and UC colons (marked arrows in middle panel; Figure 4-18) and the expression 
of CFTR protein was unchanged in UC-affected colon compared to the normal ( marked 
arrows in lower panel; Figure 4-18).  In order to quantitate the relative changes in protein 
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Figure 4-16. iNOS, CFTR and NHERF2 expression profiles in UC-affected human 
colon tissue 
 
Normalized intensities of mRNA expression of iNOS, CFTR, and NHERF2 from human 
mRNA expression data sets in colonic biopsies from normal and active IBD-suffering 
individuals. Data represent the mean ± SEM (n=10-11 per group). 
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Figure 4-17. H&E stained normal and UC-affected human colon tissue sections 
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Figure 4-18. Immunostaining for iNOS, CFTR and NHERF2 expression in normal 
and UC-affected human colon sections 
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expression of iNOS, CFTR and NHERF2 ImageJ was used and mean gray values were 
obtained as depicted in the form of bar-graphs in Figures 4-19A through 4-19C. 
 
 In order to demonstrate that there are high amounts of iNOS associated with the 
plasma membrane in IBD, Total internal reflection microscopy (TIRFM) was performed 
on the normal and UC-affected tissue present close to the coverslip. TIRFM can visualize 
single molecule fluorescence with high resolution to capture events taking place at or 
near the plasma membrane within a span of 200 nm (124). The thickness of plasma 
membrane is approximately 8 Å. TIRFM is based on the generation of an evanescent 
wave at the water-glass interface as a result of the phenomenon of total internal reflection. 
The evanescent electromagnetic field decays exponentially from the interface and can 
penetrate up to 200 nm into the sample medium and therefore, falls within the range of 
visualizing basal plasma membrane. UC-affected and -unaffected tissues were stained 
with primary mouse monoclonal iNOS antibody followed by anti-mouse Alexa-fluor-488 
secondary antibody. Antibody stained slides were excited at 488 nm and imaged using 
the TIRF module of the microscope. Using TIRFM, we could identify iNOS clusters at 
the plasma membrane in UC biopsies suggestive of its involvement in spatially restricted 
signaling complexes at the plasma membrane (marked arrows; Figure 4-20). The data 
also points to the direction that in IBD epithelial cell membranes are enriched with iNOS;  
therefore, at these membranes the iNOS-NO-sGC-cGMP pathway will be predominantly 
operative.  
 
In order to validate our in vitro data on the pathophysiological existence of iNOS-
NHERF2 interaction, an IBD simulating animal model of chemically-induced colitis 
involving oral administration of DSS was developed. Specifically the model was tested in 
C57BL/6 Nherf2
+/+
 vs. Nherf2
-/-
 mice and the immunoblot shows the absence of 
NHERF2 in Nherf2
-/-
 mice (Figure 4-21A). Kidney tissue was included for the western 
blot analysis as NHERF proteins are highly abundant in the kidney. Please note that the 
DSS-colitis model closely relates to UC conditions and the associated iNOS-upregulation 
and is also the most appropriate model to study UC (75). DSS administered in the water 
for 7 days induces severe acute colitis in mice. Colon tissues from different groups were 
excised and processed for histological staining. The microscopic sections of the DSS-
challenged colons from the Nherf2
+/+  
and Nherf2
-/-
 mice groups showed a range of 
histopathological features characteristic of DSS-induced colitis, including mucosal edema, 
epithelial cell and crypt damage, and immune cell infiltrates characterizing an 
inflammatory colon (Figure 4-21B). Histological scores were also quantified and no 
significant differences were observed between Nherf2
+/+ 
and Nherf2
-/-
 mice (Figure 
4-21B). iNOS-specific immunostaining confirmed similar upregulation of iNOS in 
response to DSS treatment in both Nherf2
+/+  
and Nherf2
-/-
 mice compared to untreated 
mice (Figure 4-22). Also, DSS-challenged mouse colons had upregulated iNOS levels at 
the apical plasma membrane of the gut epithelia (marked arrows; Figure 4-22). Therefore, 
the absence of NHERF2 does not affect the expression of iNOS under colitis. Therefore, 
consequences of depleted NHERF2 will be on iNOS trafficking to the plasma membrane 
as demonstrated in Figures 4-10 and 4-12. Moreover, it will also lead to reduced iNOS 
involvement in highly localized signaling at specialized plasma membrane microdomains. 
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Figure 4-19. Quantitated iNOS, CFTR and NHERF2 expression in normal and 
UC-affected human colon sections  
 
Bar-graphs represent quantification of (A) iNOS, (B) CFTR and (C) NHERF2 
expressions as mean gray values in normal and UC-affected human colon sections. Data 
represent the mean ± SEM; ****P < 0.001, ns= non-significant determined using 
student’s t-test. 
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Figure 4-20. iNOS clusters at the plasma membrane in UC-affected human colon 
epithelia 
 
TIRF images of normal and UC-affected human colon tissues immunostained for iNOS 
depicting organization of iNOS into clusters in UC-affected human colon tissue (marked 
arrows). 
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Figure 4-21. DSS-colitis in Nherf2
+/+
 and Nherf2
-/- 
mice  
 
(A) Immunoblot for NHERF2 expression in Nherf2
+/+ 
and Nherf2
-/- 
mouse kidney and 
colon lysates. (B) H&E stained untreated (upper panel) and DSS-treated (lower panel) 
Nherf2
+/+
 (left panel) and Nherf2
-/-
 (right panel) mouse colon sections. Bar graph 
represents the histology score of the colon sections from DSS-treated Nherf2
+/+
 and 
Nherf2
-/- 
mice. Data represent the mean ± SEM (n=3-5); ns= non-significant. 
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Figure 4-22. iNOS expression in DSS-colitis 
 
iNOS specific immunostained DSS-treated and untreated Nherf2
+/+
 and Nherf2
-/- 
mouse 
colon sections. Numbers 1-4 indicate the representative images of the four groups of 
mouse. Bar graph represents the quantitation of the iNOS expression in the sections from 
DSS-treated and untreated Nherf2
+/+
 and Nherf2
-/- 
mice. Data represent the mean ± SEM 
(n=4 regions of interest); *P < 0.05, **P < 0.01 determined using student’s t-test. 
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Interaction of iNOS and NHERF2 in UC-affected human colon tissue was 
qualitatively determined using proximity ligation assay (PLA). The interaction between 
two proteins appears as red PLA signal if the specific antibodies binding to the proteins 
are proximal to each other within a span of 40 Å and many previous studies have 
validated the application of the assay in determining protein complexes and co-
localizations in vivo (125, 126). The advantage of this assay is the ability to determine 
protein-protein interactions in tissues rather than limiting to a cell system and also, the 
assay can be used with the fixed tissues and cells unlike FRET-based assays. 
Fundamental approach of the PLA assay is labeling the cells or tissue with the antibodies 
specific to proteins of interest, followed by addition of species specific probes conjugated 
with oligonucleotides. If the proteins are present and interacting in the right proximity 
required for successful PLA, there will be a polymerization reaction of the conjugated 
nucleotides, incorporating fluorescent nucleotides and generating a signal termed as the 
PLA signal. We observed significant amount of PLA signals at the plasma membrane of 
the colon epithelial cells in UC-affected tissues signifying the interaction between iNOS 
and NHERF2 (lower panel, marked arrows; Figure 4-23) while almost no PLA signal 
was observed in normal human colon tissues (upper panel; Figure 4-23).  
 
In order to demonstrate the physiological existence of a CFTR-NHERF2-iNOS 
macromolecular complex in the DSS-induced colitis model, colon mucosal epithelial 
cells scraped from the control and DSS-treated animals were used and CFTR and iNOS 
were probed for in the immunoprecipitated complex with purified GST-NHERF2 
immobilized on glutathione beads. CFTR could be detected in a complex with GST-
NHERF2 in both control and DSS-treated colon mucosal epithelial cells while iNOS was  
detected in the complex in DSS-treated tissue only (Figure 4-24). To ensure the 
physiological existence of a CFTR-NHERF2-iNOS macromolecular association, co-
immunoprecipitation was performed in DSS-treated Nherf2
+/+
 mouse colon with iNOS 
specific antibody and CFTR and NHERF2 were detected in the complex with iNOS 
(Figure 4-25). Thus, with the evidence of induced expression of iNOS at the apical 
plasma membrane possibly due to its interaction with NHERF2 in IBD, there is a high 
probability of involvement of iNOS in contributing to altered vectorial physiology in the 
IBD gut. 
 
 
iNOS Potentially Constitutes cGMP Microdomains  
 
 Because we previously observed that iNOS is overexpressed at the apical plasma 
membrane in gut epithelial cells, we tested whether iNOS contributes to cGMP 
production at the plasma membrane. To this end, ratiometric FRET was performed to 
monitor cGMP dynamics in HEK-293 cells expressing a membrane-bound cGMP sensor, 
m-Cygnet 2.1. Ratiometric FRET is a FRET-based procedure customized to monitor the 
changes in the levels of small molecules such as Ca
2+
, cAMP and cGMP based on the 
specific sensitivities towards these molecules of unimolecular FRET-based sensors which 
comprise of a donor and acceptor fluorophore in the same molecule (127-129). cGMP-
specific sensors termed as Cygnets are very sensitive to cGMP levels in the nanomolar 
range and allow detection of spatial associations of cGMP production inside the cell 
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Figure 4-23. iNOS-NHERF2 interaction in UC-affected human colon tissue 
 
PLA in human colon tissue sections depicting interaction between iNOS and NHERF2 in 
UC-affected human colon tissue sections appearing as a red signal termed the PLA signal 
(marked arrows).  
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Figure 4-24. Pull-down of CFTR and iNOS using purified GST-NHERF2 in DSS-
treated colon mucosa 
 
Western blot data depicting pull-down of proteins from colon mucosa tissue lysate from 
DSS-treated and untreated mice with purified GST-NHERF2 (20 µg) and probed for 
CFTR (left) and iNOS (right). 
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Figure 4-25. Immunoprecipitation of CFTR-NHERF2-iNOS macromolecular 
complex in DSS-treated colon tissue 
 
Western blot data depicting colon tissue lysate from DSS-treated mice co-
immunoprecipitated with anti-iNOS antibody and probed for CFTR and NHERF2. 
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(130). Increase in the cGMP is monitored by calculating the ratio of CFP/FRET which 
has been designed to increase upon binding of cGMP to the sensor. The membrane-bound 
sensor was generated by inserting the myristoylation-palmitoylation site into the N-
terminus of cygnet 2.1 backbone sequence which anchors the protein in the plasma 
membrane (Figure 4-26). Using this sensor we can specifically monitor cGMP dynamics 
at the plasma membrane. There was an increase in cGMP levels at the plasma membrane 
(equivalent to increase in CFP/FRET ratio) upon adding the cGMP-elevating agent, 
zaprinast, and cells that overexpressed iNOS showed a higher baseline and zaprinast-
induced CFP/FRET ratio (i.e., level of cGMP is high) at the plasma membrane (Figure 
4-27), all of which suggested that iNOS contributes to cGMP generation at the plasma 
membrane. Although, it is understood that NO is quite a diffusible molecule however, the 
predominant association of iNOS at the plasma membrane as clusters in UC colon 
epithelia corroborates the idea of enrichment of the membrane with localized NO 
signaling. The evidence of increased cGMP in the presence of iNOS at the plasma 
membrane suggests close proximity of iNOS and soluble guanylate cyclase and the 
feasibility of localized generation of cGMP at the membrane. Therefore, it can be 
concluded that compartmental NO-cGMPsignaling may exist at the plasma membrane. 
  
It is understood that iNOS-governed microdomains would involve an active NO-
cGMP pathway with the sGC present in the proximity. Since cGMP is a known activator 
of CFTR chloride channel function, we tested the impact of iNOS overexpression on 
CFTR function. Towards this end, cGMP modulators, zaprinast and sildenafil, which are 
phosphodiesterase-5 inhibitors (PDE5-inh; PDE5 is a cGMP-specific diesterase) were 
used in various cell culture studies. An added explanation to the use of PDE5-inh is the 
close communication and colocalization of NOS-sGC machinery with PDE5 as 
demonstrated previously in cardiac myocytes (131, 132). We detected significant 
amounts of PDE5 in HEK-293 and HT29-CL19A cells and epithelial cells from pig colon 
(Figure 4-28). It was mostly detected as a cytosolic protein with small amounts of the 
protein associated with the membrane fraction (Figure 4-28; left). 
 
 
iNOS Physical Interaction with CFTR Forms the Basis of CFTR Channel Activity 
Potentiation 
 
CFTR is localized primarily at the apical plasma membrane of gut epithelial cells 
and can be found enriched in the isolated membranes of pig colon epithelial cells as 
shown in Figure 4-29 (34). In view of apical localization of iNOS and its involvement in 
cGMP production at the apical plasma membrane, it is likely that iNOS functionally 
couples with CFTR and augments CFTR function at the plasma membrane via the NO-
cGMP pathway. CFTR-mediated halide influx was determined in HEK-293 cells with 
(here referred to as HEK-293-N) or without (here referred to as HEK-293-S) NHERF2 
knockdown and overexpressing Flag-CFTR, iNOS and a YFP-based halide sensor, 
pCDNA3-TM-Cl
-
. CFTR mediated I
-
 influx was monitored in response to extracellular 
addition of zaprinast (250 µM) in 136 mM NaI which activated CFTR function and lead 
to decreased intracellular YFP fluorescence (133). CFTR-dependent halide flux in 
response to zaprinast reduced by 28% in the cells having the partially compromised  
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Figure 4-26. Generation of m-cygnet 2.1 
 
Schematics of how membrane-bound cGMP sensor m-cygnet 2.1 was generated. 
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Figure 4-27. iNOS potentially constitutes cGMP microdomains at the plasma 
membrane 
 
Representative pseudocolor images of CFP/FRET emission ratio before (time=0) and 
after adding 250 µM zaprinast (time =10 min) in HEK-293 cells, transiently expressing 
membrane-bound cGMP sensor m-Cygnet 2.1, and transfected with pCDNA3 empty 
vector (upper panel) and pcDNA3-iNOS (lower panel). Representative line graph to show 
CFP/FRET emission ratio change over time upon adding the agonist. Bar graph 
represents baseline and zaprinast-induced CFP/FRET emission ratio in empty vector vs. 
iNOS-transfected HEK293 cells. All data are mean ± SEM (n=3); *P < 0.05 as 
determined using student’s t-test.  
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Figure 4-28. PDE5 expression in various cell systems 
 
Western blot data to show PDE5 expression in post-nuclear supernatant (PNS), cytosol 
(CYT) and membrane (MEM) fractions of the pig distal colon tissue lysate (left) and, in 
HEK-293 and HT29-CL19A total cell lysate (right).  
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Figure 4-29. CFTR expression in colon mucosal epithelial cells 
 
Western blot data to show CFTR expression in post-nuclear supernatant (PNS), cytosol 
(CYT) and membrane (MEM) fractions of the pig distal colon tissue lysate.  
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macromolecular complex of CFTR and iNOS due to NHERF2 knockdown compared to 
that in the cells with intact NHERF2 (Figure 4-30A). CFTR function was not 
significantly different in HEK-293-S-Flag-CFTR and HEK-293-N-Flag-CFTR (Figure 
4-30B). 
 
 
iNOS Potentiates CFTR Chloride Channel Function in a Cell Inflammatory Model 
 
PDE5-inh-dependent stimulation of CFTR currents has been demonstrated in lung 
airway cells (6). Viagra, a derivative of PDE5-inh, is used for treating male impotence, 
and, interestingly, patients who take the drug have diarrhea as a side-effect (134). We 
demonstrated that zaprinast increases CFTR-dependent short-circuit currents (8) in 
HT29-CL19A cells in a dose dependent manner (Figure 4-31A). We also measured 
iodide efflux rate in HT29-CL19A cells, and, consistent with the Isc measurement, 
zaprinast augmented CFTR function in the treated cells (Figure 4-31B). Forskolin a 
global activator of AC and CFTR chloride channel function was used as a positive 
control. It was observed that the effect seen with zaprinast on CFTR-function was small 
which may be accounted by the nature of how most of the PDEs function i.e. in a highly 
compartmentalized fashion. Therefore, high concentration of zaprinast was used for the 
studies. The nature of how PDEs usually function in cells has been reviewed in Chapter 1. 
In order to elucidate the possibility of CFTR and iNOS physical and functional coupling 
at the plasma membrane, polarized HT-29CL19A cells were immunostained for CFTR 
and iNOS. HT29-CL19A cells endogenously express CFTR and iNOS was exogenously 
overexpressed in these cells. Immunofluorescence stained polarized cells demonstrated a 
high abundance of CFTR and iNOS at the apical plasma membrane and these two 
proteins are partially co-localized (Figure 4-32). Colon mucosal epithelial cells are 
known to be the major contributors of intestinal inflammation in IBD, so we investigated 
CFTR function in vitro in HT29-CL19A cells in response to an inflammatory challenge. 
These colon epithelial cells reportedly showed induced iNOS mRNA and increased 
nitrite levels in response to various cytokines (135). We simulated inflammatory 
conditions in HT29-CL19A cells by subjecting the cells to a cytokine mix or cytomix for 
48 h. The rationale of inducing inflammation in order to study outcomes of iNOS up-
regulation on CFTR function is to present a more relevant physiological model 
representative of in vivo inflammatory conditions. Subsequently, the relative change in 
iNOS-specific mRNA levels was determined using real-time PCR. iNOS expression 
increased almost 6-fold in response to the cytokines compared to the untreated controls 
(Figure 4-33). A small increase in the expression levels of CFTR and NHERF2 was also 
observed (Figure 4-33). We monitored Isc and measured iodide efflux rate in HT29-
CL19A cells pretreated with or without cytomix. After establishing basal currents or 
basal iodide secretion, cells were incubated with an inducer of iNOS, L- arginine (1 mM), 
for 15 min. CFTR was then activated with 250-400 µM zaprinast. CFTR Cl
-
 channel 
function increased by 1.5- to 2-fold in cytomix-treated cells compared to the untreated 
cells (Figure 4-34). The difference of the effect on CFTR function observed between 
cytomix-treated and untreated sample was not dramatic which might be possible due to 
highly compartmentalized activation of CFTR within iNOS microdomains and it can be 
speculated that additional factors might be required in vivo in order to observe massive 
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Figure 4-30. Knockdown of NHERF2 expression compromises CFTR-iNOS 
functional coupling 
 
(A) Averaged representative traces of CFTR-mediated I
-
 influx in HEK-293-S (scrambled 
siRNA) and HEK-293-N (NHERF2 siRNA) cells overexpressing Flag-CFTR and iNOS 
in response to 250 µM zaprinast. PAR refers to the cells with no Flag-CFTR and iNOS. 
Quantification of the data represented as change in YFP fluorescence (n = 6). (B) 
Averaged representative traces of CFTR-mediated I
-
 influx in HEK-293-S (scrambled 
siRNA) and HEK-293-N (NHERF2 siRNA) overexpressing Flag-CFTR in response to 
250 µM zaprinast (n=4-6). Data are mean ± SEM; **P < 0.01 as determined using 
student’s t-test. 
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Figure 4-31. Zaprinast induced CFTR-chloride channel function 
 
(A) Representative traces of CFTR-mediated short circuit currents (Isc) currents in 
polarized HT29-CL19A cells treated with various concentrations of zaprinast. CFTRinh-
172 was added to the apical side at the end of the experiment. (B) Line graph represents 
CFTR-mediated iodide efflux rate in HT29-CL19A cells activated with forskolin (50 µM) 
or zaprinast (250 µM). 
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Figure 4-32. Localization of CFTR and iNOS in polarized HT29-CL19A cells  
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Figure 4-33. iNOS, CFTR and NHERF2 expression in cytomix challenged colon 
epithelial cells 
 
The bar graph represents the fold change in iNOS, CFTR, NHERF2 transcripts by using 
real-time PCR (TaqMan probe-based method) in HT29-CL19A cells treated with cytomix 
for 48 h. Data represent the mean ± SEM (n=3). 
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Figure 4-34. CFTR chloride channel function in cytomix-treated colon epithelial 
cells 
 
(A) Representative trace of CFTR-mediated short circuit currents (Isc) in polarized HT29-
CL19A cells treated with cytomix for 48 h vs. untreated. Bar graph represents the 
maximal increase in Isc (cytomix treated vs. untreated cells) (n=3). (B) Bar-graph to show 
the maximal increase in iodide efflux rate to monitor CFTR activity in cytomix-treated 
vs. untreated HT29-CL19A cells (n=6). Data are mean ± SEM; *P < 0.05, **P < 0.01 as 
determined using student’s t-test. 
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activation of CFTR chloride channel function. Also, an inflamed colon would present 
massive and highly active iNOS to regulate CFTR function which is challenging to 
achieve in a cell culture model. 
 
Based on the abovementioned findings, it can be concluded that tight association 
of iNOS with the apical plasma membrane in IBD and polarized colon epithelial cells 
would form the basis of iNOS-dependent stimulation of CFTR in a highly 
compartmentalized fashion at the plasma membrane. 
 
 
Inhibition of CFTR and iNOS Activity Attenuates Diarrhea in DSS-induced Colitis 
 
No convincing data exists on the role of CFTR in IBD-associated diarrhea and 
many in vivo animal and human studies have emphasized that anion secretion may not be 
altered in colitis (103). With the major role of CFTR in regulation of fluid regulation 
across intestinal epithelial and pathogenesis of secretory diarrhea, it is considerably 
important to conclusively determine the role of CFTR in the pathogenesis of diarrhea in 
IBD (136). Ma et al. developed a highly specific thiozolidinone CFTR-inhibitor 
(CFTRinh-172) which could significantly attenuate CTX-induced diarrhea in mice when 
administered intraperitoneally (150 µg/kg for 6 h) or orogavaged (250 µg/kg for 6 h) in 
these mice (137). More than 90% reduction in the CTX-induced fluid secretion could be 
observed in mice orogavaged with the inhibitor. Based on these observations and highly 
specific action of CFTRinh-172 on CFTR, in order to conclusively determine if CFTR has 
a contribution in UC-associated diarrhea, colitis was developed in C57BL/6 mice using 
5% DSS in the presence and absence of intraperitoneal administration of CFTRinh-172 
(150 µg/kg) 5-day post DSS treatment. Preference was given to IP administration than 
orogavaging as the latter may have an effect on drinking water uptake by the mice. 
Control animals for the experiment included mice intraperitoneally administered with or 
without CFTRinh-172 (150 µg/kg) and normal autoclaved drinking water. Mice treated 
with DSS develop diarrhea and suffer from weight loss (117). The experimental layout of 
the experiment is represented and changes in the body weights of all the mice in each 
group were monitored every day in the span of the experiment (Figure 4-35). 
Administration of CFTR inhibitor was based on the appearance of symptoms in DSS-
treated animals. Animals started showing symptoms on the 4
th
 day of DSS-treatment. 
Mice were sacrificed on the 8
th
 day, and colons were removed for calculation of wet/dry 
weight, relative colon length, bleeding score and histological examination. Mice 
administered with CFTRinh-172 exhibited reduced weight loss (25%) and fluid secretion 
compared to the untreated animals in the DSS group (Figures 4-35 and 4-36). 
Administration of CFTRinh-172 improved colitis conditions which included, less-reduced 
colon length, rectal bleeding score, wet/dry weight ratio compared to sole DSS treatment 
(Figure 4-37). In the absence of CFTRinh-172, the wet/dry weight of colon was higher by 
35% vs. when present (Figure 4-37). Interestingly, the histology score was not 
significantly altered with the inhibitor compared to the DSS-alone treatment (Figure 
4-38). To the best our knowledge, this is the first study which sought to evaluate the role 
of CFTR in DSS-induced colitis and our data demonstrated that CFTR contributes 
significantly to DSS-induced diarrhea which can be extended to IBD-associated diarrhea.  
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Figure 4-35. Inhibition of CFTR function causes partial protection against weight 
loss in DSS-colitis 
 
A layout of the experiment involving CFTRinh-172 treatment in DSS colitis model. Line 
graph shows the mouse total body weight measurements over a period of 7 days of the 
four-mice group; saline ± DSS treatment and CFTRinh-172 ± DSS. No DSS treatment 
groups had 3 mice each. DSS treatment group comprised of 5-8 mice. Bar-graph to show 
the total change in body weight of the mice on day 7 in DSS± CFTRinh-172 experimental 
group. Data are mean ± SEM; *P < 0.05 as determined using student’s t-test. 
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Figure 4-36. Inhibition of CFTR function attenuates fluid secretion in DSS-colitis 
 
Representative separated mouse colons of the various treatment groups. Upper panel 
shows colon of the mice with no DSS ± CFTRinh-172. Lower panel represents the colon 
isolated from mice in the DSS ± CFTRinh-172 treatment experimental group.  
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Figure 4-37. Inhibition of CFTR function causes partial protection in DSS-colitis 
 
Bar-graphs show the assessments of various disease parameters of the DSS-induced 
colitis including bleeding and stool score and wet to dry weight ratio of the fecal pellets 
in the mice not receiving or receiving intraperitoneal injection of CFTRinh-172. X-Y 
scatter plot depicts the colon lengths of the mice in various groups. Control groups had 3 
mice each. DSS treatment group comprised of 7-8 mice per group for CFTRinh-172 
treatment. Data are mean ± SEM; *P < 0.05 as determined using student’s t-test. 
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Figure 4-38. Histological scores are unaltered in the presence of CFTR inhibitor in 
DSS-colitis 
 
H&E stained colon sections of the mice from DSS ± CFTRinh-172 treatment experimental 
group Bar graph represents the histology score of the colon sections. Data represent the 
mean ± SEM (n=6-12); ns= non-significant as determined using student’s t-test. 
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These observations have important clinical implications that CFTR inhibitors can have 
beneficial effects in the therapeutic intervention of IBD.  
  
In order to elucidate the role of iNOS in DSS-induced diarrhea and colitis, we 
investigated the consequences of inhibiting iNOS activity in vivo in DSS-treated mice on 
fluid secretion in the colon. Previous studies have consistently determined that loss of 
iNOS causes reduced severity of DSS-induced colitis (138). Ablation of iNOS in TNBS-
colitis has generated equivocal results (75). However, it was concluded that the acute 
phase of colitis is critically affected by iNOS presence and activity in TNBS colitis and 
the absence of iNOS increases susceptibility to mucosal injury (111, 139). Based on these 
studies it can be understood that iNOS can have varied contribution in even closely 
related forms of inflammation. Therefore, generalization of an iNOS-dependent 
phenomenon must be precariously applied to other related gastrointestinal inflammatory 
disorders. Whether there exists an organ-specific phenotype of CFTR-iNOS 
macromolecular association in other organ-related inflammatory conditions needs to be 
further studied and evaluated.Studies involving use of NOS inhibitors have also 
generated mixed information and the inconsistencies largely stemmed from the narrow 
window of selectivity and specificity towards iNOS of these inhibitors and it has been 
inferred that certain NOS activity from nNOS might be essential for keeping the gut 
healthy (75, 112). Exogenous NO-donors could stimulate electrolyte secretion in guinea 
pig mucosa with the role of endogenous NO largely undetermined (140).  
 
A recently published study documented the curative effects of iNOS inhibition 
using L-NIL on smoke induced pulmonary emphysema where it could prevent the 
development when co-administered with the smoke threat and could also reverse 
deterioration associated with the established emphysema (141). Other studies have 
reported specific action of L-NIL in the resolution of several other inflammatory profiles 
and in modulating inflammatory phenotypes in different models of intestinal 
inflammation. Considering the therapeutic effects of L-NIL on resolution of an 
inflammatory profile, we tested the effects of iNOS in DSS-colitis murine model and also, 
determined how endogenous NO generated from iNOS can alter fluid secretion in colon. 
L-NIL was administered intraperitoneally in a temporal variation in DSS-challenged 
wild-type mice. The temporal component of iNOS treatment is critical in view of 
suggested correlation between stage of iNOS inhibition and its outcome on disease 
activity index in experimental colitis models as mentioned previously (75). Fluid 
secretion was attenuated in L-NIL treated mice colons compared to the untreated (Figure 
4-39). Animals treated with L-NIL one day after DSS-treatment appeared healthier and 
had significantly smaller weight loss (16.3%) compared to the mice receiving 
intraperitoneal saline administration (Figure 4-39). Interestingly, mice which were 
treated with L-NIL three and five days after DSS-treatment trended to show improvement 
in the body weights compared to the control, however, it was less significant compared to 
the animals treated with L-NIL one day after colitis induction. No difference was 
observed in the animals which were administered with L-NIL or saline without DSS in 
the drinking water. Also, the disease activity parameters were significantly improved 
upon L-NIL treatment compared to the controls (Figure 4-40) which indicates the 
curative effects of L-NIL on DSS-induced colitis. The histological scores were improved  
   85 
 
 
 
 
 
Figure 4-39. Inhibition of iNOS function causes partial protection against weight 
loss and attenuates fluid secretion in DSS-colitis 
 
A layout of the experiment involving L-NIL treatment in DSS colitis model. Bar-graph to 
show the maximal change in body weight of the mice on day 7 in DSS± L-NIL 
experimental group. DSS treatment group comprised of 4-5 mice per group. The right 
panel represents the colon isolated from mice in the DSS ± L-NIL treatment group. 
Arrows are marked to show the extent of fluid secretion in the colon. Data are mean ± 
SEM; **P < 0.01 as determined using student’s t-test. 
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Figure 4-40. Inhibition of iNOS function causes partial protection against DSS-
colitis 
 
The bar-graphs show the assessments of various disease parameters of the DSS-induced 
colitis including bleeding and stool score and wet to dry weight ratio of the fecal matter 
in the mice not receiving or receiving intraperitoneal injection of L-NIL. X-Y scatter plot 
depicts the colon lengths of the mice in various groups. Control groups had 3 mice each. 
The DSS treatment group comprised of 4-5 mice per group for L-NIL treatment. Data are 
mean ± SEM; *P < 0.05 as determined using student’s t-test. 
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with L-NIL treatment (Figure 4-41) Levels of NO in the homogenized colon tissue were 
quantified as nitrite using Griess reagent and normalized with the total protein 
concentration. DSS-exposed colon tissues were enriched with high amounts of NO 
compared to the unexposed tissue (Figure 4-42). The amount of NO was substantially 
reduced in the L-NIL treated animal group. cGMP levels were also determined using 
ELISA-based method and were found to be elevated in DSS-treated mice and decreased 
in response to L-NIL treatment (Figure 4-42). The data signifies that NO-cGMP pathway 
is actively operating in the DSS-colitis and is driven by up-regulated levels of iNOS. 
Also, effects observed with L-NIL treatment on DSS-colitis correctly correlate the 
contribution of endogenous NO contributed by highly active iNOS to increased fluid 
secretion in the affected mice .Also, it can be inferred that a right coordination of iNOS 
inhibition and its effect on other disease features of IBD than diarrhea can be explored as 
a potential therapeutic approach to control UC. Although, iNOS will be expressed by 
inflammatory cells also but secretory phenotype will be largely a contribution of 
epithelial cells. 
 
 
Diarrhea Is Attenuated in Nherf2
-/-
 Mice in DSS- and TNBS-induced Colitis 
Individuals suffering from IBD show severe diarrhea and weight loss. Given that 
potentiation of CFTR channel function happens in a compartmentalized manner through 
NHERF2-mediated formation of the CFTR-iNOS complex, we investigated the 
consequences of disrupting the compartmentalized response by uncoupling the protein-
interactome as would be the case in Nherf2
-/-
 mice. It is now being established that 
several macromolecular signaling complexes can become pathophysiological (46). 
Intuitively formation of macromolecular complexes is an evolutionary advantage for cell 
survival with the rationale that it prevents the dramatic functional effects of a protein and 
at the same time would contain the pathophysiological aspects of protein function. The 
current study emphasizes the fact the CFTR becomes pathophysiological in certain 
microdomains at the plasma membrane in IBD. In case of IBD, plasma membrane gets 
enriched with such microdomains and therefore, would simulate mass activated CFTR. 
The question arises how this mode of CFTR function regulation by iNOS in localized 
domains would be different from freely diffusing iNOS? The definitive advantage of 
compartmentalized regulation of CFTR is the selective and specific activation of CFTR 
and this also allows a major proportion of iNOS function to be channeled to CFTR 
regulation. Formation of a macromolecular complex also determines the nature of action 
of iNOS in the gut mucosa which would be predominantly vectorial. Our in vitro data 
established that the CFTR-NHERF2-iNOS macromolecular signaling complex increases 
CFTR function and that may have pathophysiological relevance to diarrhea in IBD. Next, 
we questioned what happens if the macromolecular complex is disrupted and if it can be 
beneficial for IBD therapeutics. DSS-induced colitis is the most widely used model that 
involves chemical-triggered manipulation of epithelial integrity/permeability and induces 
very reproducible severe acute colitis characterized by bloody diarrhea, ulcerations and 
granulocytes infiltrations (142). It is a particularly useful model to study the contribution 
of innate immune mechanisms of colitis and it gives the flexibility of inducing acute, 
chronic, or relapsing conditions of colitis with manipulations according to the  
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Figure 4-41. Inhibition of iNOS function improves histological scores in DSS-colitis 
 
H&E stained colon sections of the mice from DSS ± L-NIL treatment experimental group 
Bar graph represents the histology score of the colon sections. Data represent the mean ± 
SEM (n=5-7); **P < 0.01 as determined by student’s t-test. 
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Figure 4-42. Inhibition of iNOS function affects NO-cGMP signaling in DSS-colitis 
 
(A) Bar graph represents nitrite levels in colon tissues in response to DSS and 
DSS+LNIL treatment (n=3 colon tissue samples). (B) Bar graph represents cGMP levels 
in colon tissues in response to DSS and DSS+L-NIL treatment (n=3-4 colon tissue 
samples). All data are mean ± SEM; ***P < 0.001 as determined using student’s t-test. 
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experimental needs. TNBS-colitis is the most widely used haptenating agent to initiate a 
CD-like intestinal inflammation in the colon and can recapitulate many of the events 
proposed to initiate and sustain human Crohn’s disease (143).  
 
We tested the differences in intestinal fluid secretion and weight loss, two 
indicators for secretory diarrhea, between Nherf2
-/- 
and Nherf2
+/+ 
mice
 
in DSS- and 
TNBS-colitis models. Fluid secretion and the extent of diarrhea were assessed by 
calculating wet to dry weight ratio (wet/dry weight). Mice were weighed on a regular 
basis for 7 and 3 days in DSS- and TNBS-colitis models, respectively. Symptoms of 
colitis (rectal bleeding, weight loss) were observed from the 4
th
 day onwards after DSS 
treatment in all DSS-treated mice irrespective of the genetic background and similar 
bleeding score and reduction in colon length was observed on day 7 in Nherf2
-/- 
and 
Nherf2
+/+ 
DSS-treated mice. No symptoms of colitis were observed in the untreated 
animals. TNBS was administered intra-rectally in ethanol based solution and mice 
demonstrated rapid weight loss on day 2 post-TNBS treatment characterizing the 
development of TNBS-induced colitis in both Nherf2
-/- 
and Nherf2
+/+ 
mice. Weight loss 
was assessed on the 7
th
 day of DSS treatment for all mice groups, and DSS-treated 
Nherf2
-/- 
mice had significantly smaller maximal weight loss compared to DSS-treated 
Nherf2
+/+ 
mice (~40%; Figure 4-43). On the 7
th
 day, colons were exteriorized, and 
wet/dry weights were calculated. Gross examination of the colons suggested relatively 
higher fluid secretion in Nherf2
+/+ 
compared to Nherf2
-/- 
mice in the DSS-treated groups, 
while no major difference was observed in the DSS-untreated group of animals (Figure 
4-44). DSS-treated Nherf2
+/+ 
mouse colon sections had ~39% higher wet/dry weight 
compared to Nherf2
-/- 
mice, and the values in the untreated mouse groups were not 
significantly different (Figure 4-45). Similar to DSS-effects, Nherf2
-/- 
were resistant to 
TNBS-induced colitis and demonstrated 65% lower maximal weight loss compared to 
Nherf2
+/+ 
mice (Figure 4-46). Nherf2
-/- 
mice exhibited lower stool consistency score and 
wet to dry weight ratio was estimated to be lower by 42% in Nherf2
-/- 
than Nherf2
+/+ 
mice 
in TNBS-colitis set-up (Figures 4-47 and 4-48). Similar histology scores were observed 
in Nherf2
-/- 
and Nherf2
+/+ 
mice in TNBS-colitis (Figure 4-49).These studies suggested 
that mice lacking NHERF2 were protected against DSS- and TNBS-induced diarrhea, 
and NHERF2 is required to mediate the functional coupling between CFTR and iNOS. 
 
 
Mass-Spectrometry of Purified iNOS 
 
The identity of the protein purified from Flag-iNOS expressing stable cell lines 
that indeed it is full-length Flag-iNOS protein was confirmed with mass spectrometry and 
also, there was a pool of data on the various proteins as potential interacting partners or 
modulators of iNOS function. Five major bands in iNOS immunoprecipitation lane were 
subjected to MS analysis as shown in Figure 4-50 and the results are shown in Tables 
4-1 to 4-5. Information on the functions of immunoprecipitated proteins was obtained 
from http://www.uniprot.org. The Mowse score was calculated to opt out randomized 
interactions of low Mowse score and keep proteins with high Mowse score.  
 
A Mowse score in peptide mass fingerprinting is a “similarity score” based on the  
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Figure 4-43. Nherf2
-/-
 mice are partially protected against weight loss in DSS-colitis 
 
An experimental layout of DSS treatment in Nherf2
+/+
 and Nherf2
-/-
 mice for a period of 
7 days. Line graph shows the mouse total body weight measurements over a period of 7 
days of the four-mice group; Nherf2
+/+
 ± DSS treatment and Nherf2
-/-
 ± DSS treatment. 
Each group had 3-4 animals. Data are mean ± SEM; **P < 0.01as determined using 
student’s t-test.  
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Figure 4-44. Nherf2
-/-
 mice exhibit reduced fluid secretion than Nherf2
+/+
 mice in 
DSS-colitis 
 
Representative exteriorized mouse colons of the various treatment groups. Upper panel 
and lower panel shows colon of Nherf2
+/+
 and Nherf2
-/-
 mice with no DSS and with DSS, 
respectively. Arrows are marked to show the extent of fluid secretion in the colon.  
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Figure 4-45. Nherf2
-/-
 mice are partially protected against diarrhea in DSS-colitis 
 
Bar-graphs show the assessments of various disease parameters of the DSS-induced 
colitis including bleeding and stool score and wet to dry weight ratio of the fecal pellets 
in the Nherf2
+/+
 and Nherf2
-/-
 mice. X-Y scatter plot depicts the colon lengths of the mice 
in various groups. Control groups with no DSS had 3 mice each. DSS treatment group 
comprised of 8-10 mice per group. Data are mean ± SEM *P < 0.05, **P < 0.01, ***P < 
0.005, ns= non-significant as determined using student’s t-test.  
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Figure 4-46. Nherf2
-/-
 mice are partially protected against weight loss in TNBS-
colitis 
 
Line graph shows the mouse total body weight measurements over a period of 3 days of 
the four-mice group; Nherf2
+/+
 ± TNBS treatment and Nherf2
-/-
 ± TNBS treatment. 
TNBS group had 5-8 animals. Data are mean ± SEM; **P < 0.01 as determined using 
student’s t-test. 
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Figure 4-47. Nherf2
-/-
 mice exhibit reduced fluid secretion than Nherf2
+/+
 mice in 
TNBS-colitis as depicted in the exteriorized colon sections  
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Figure 4-48. Nherf2
-/-
 mice are protected against diarrhea in TNBS-colitis 
 
Bar-graphs show the measured stool score and wet to dry weight ratio of the fecal matter 
in the TNBS-treated Nherf2
+/+
 and Nherf2
-/-
 mice. TNBS treatment group comprised of 
8-10 mice per group. Data are mean ± SEM; *P < 0.05., **P < 0.01 as determined using 
student’s t-test.  
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Figure 4-49. Histological scores are not different in Nherf2
-/-
 mice than Nherf2
+/+
 
mice in TNBS-colitis 
 
H&E stained colon sections of the TNBS treated Nherf2
+/+
 and Nherf2
-/-
 mice. Bar graph 
represents the histology score of the colon sections. Data represent the mean ± SEM 
(n=5-10); ns= non-significant as determined using student’s t-test. 
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Figure 4-50. Immunoprecipitation of full-length HA-iNOS for mass-spectrometric 
analysis of bands 1-5 as marked 
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Table 4-1. Mass-spectrometric analysis of immunopurified iNOS (Band 1) 
 
Protein  Mowse score  Function 
Nitric oxide synthase, 
inducible NOS2  
 12890  NO-synthesis 
Serine/threonine-protein 
kinase Chk1  
 80  Cell cycle, DNA damage, DNA 
repair 
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Table 4-2. Mass-spectrometric analysis of immunopurified iNOS (Band 2) 
 
Protein   Mowse score  Function 
Heat shock protein HSP 
90-beta  
 2728  Chaperone  
Heat shock protein HSP 
90-alpha  
 2122  Chaperone 
Arf-GAP with coiled-
coil, ANK repeat and PH   
domain-containing 
protein 2  
 818  GTPase-activating protein 
Putative heat shock 
protein HSP 90-beta 2  
 725  Chaperone  
Heat shock cognate 71 
kDa protein  
 626  Chaperone 
Putative heat shock 
protein HSP 90-beta 4  
 415  Chaperone  
Interleukin enhancer-
binding factor 3  
 367  Transcription 
Heat shock 70 kDa 
protein 6  
 296  Chaperone  
Pantothenate kinase 4   241  Co-A synthesis 
Heat shock protein 75 
kDa, mitochondrial  
 185  Chaperone 
Endoplasmin   158  Chaperone, proper folding of Toll-
like receptors, ER-associated 
degradation 
A-kinase anchor protein 
8-like  
 135  Helicase A binding protein 
 
 
Protein arginine N-
methyltransferase 5  
 123  Protein methylation 
Golgi-specific brefeldin 
A-resistance guanine  
 121  Post-Golgi vesicle-mediated 
transport and regulation of Arf-
GAP 
E3 UFM1-protein ligase 
1  
 115  Negative regulation of NF-kappaB 
transcription factor activity and 
possibly acts as tumor suppressor 
78 kDa glucose-regulated 
protein  
 107  Chaperone and is involved in the 
activation of unfolded protein 
response in response to glucose 
starvation 
Probable Xaa-Pro 
aminopeptidase 3  
 99  Protein processing and proteolysis, 
implicated in polycystic kidney 
disorders 
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Table 4-2. Continued 
 
Protein   Mowse score  Function 
Mannosyl-
oligosaccharide 
glucosidase  
 87  Protein N-linked glycosylation via 
asparagine 
Catenin beta-1   80  Component of Wnt-pathway and 
also implicated in multiple-organ 
cancer 
Acyl-CoA 
dehydrogenase family 
member 11  
 78  Fatty-acid metabolism 
Junction plakoglobin   75  Adherens junction organization 
and cell migration 
Serine/threonine-protein 
kinase TBK1  
 73  Triggers I-kappaB kinase/NF-
kappaB cascade and regulator of 
innate immune response 
Sulfhydryl oxidase 2   71  Disulfide bond formation and 
synthesis of H2O2 
Carnitine O-
palmitoyltransferase 1, 
liver isoform  
 68  Lipid metabolism 
Melanoma-associated 
antigen D1  
 67  Ubiquitination and apoptosis 
Cullin-5   65  Ubiquitination and response to 
osmotic stress 
Pyridoxal-dependent 
decarboxylase domain-
containing protein 20    
 65  Carboxylic acid metabolic process 
Dermcidin   65  Proteolytic and antimicrobial 
Ran-binding protein 9   61  Can act as an adapter protein to 
couple membrane receptors to 
intracellular signaling pathways, 
also involved in microtubule 
nucleation and axonal guidance. 
Coiled-coil domain-
containing protein 8  
 60  Negative regulation of 
phosphatase activity, implicated in 
dwarfism 
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Table 4-3. Mass-spectrometric analysis of immunopurified iNOS (Band 3) 
 
Protein   Mowse score  Function 
Calcium-binding 
mitochondrial carrier 
protein  
 330  Malate-Aspartate shuttle, 
gluconeogenesis 
Stress-induced-
phosphoprotein 1  
 236  Assembly of molecular chaperones 
HSC70 and HSP90 complex 
Insulin-like growth factor 
2 mRNA-binding protein 
3  
 159  Regulation of cytokine 
biosynthesis 
Stress-70 protein, 
mitochondrial  
 154  Chaperone; negatively regulates 
apoptosis 
Dolichyl-
diphosphooligosaccharide 
glycosyltransferase 
subunit 1  
 76  Glycosyltransferase activity 
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Table 4-4. Mass-spectrometric analysis of immunopurified iNOS (Band 4) 
 
Protein   Mowse score  Function 
E3 ubiquitin-protein 
ligase  
 787  Ubiquitination and negatively 
regulates mTOR pathway 
Serine/threonine-protein 
kinase 38  
 321  Negative regulator of MAP3K1/2 
signaling involved in regulation of 
NF-kappaB signaling 
Serine/threonine-protein 
phosphatase 2A 55 kDa 
regulatory subunit B 
alpha isoform 
 196  Binds oncogene TP53 which 
contributes to transformation and 
malignancy 
Serine 
palmitoyltransferase 1  
 181  Sphingolipid metabolism and  
homeostasis 
Glutamate dehydrogenase 
1 (GLUD1) 
 109  Oxidation of Glutamate; Defects in 
GLUD1 are the cause of familial 
hyperinsulinemic hypoglycemia 
type 6 
MAP kinase-activated 
protein kinase 5  
 90  Tumor suppressor 
serine/threonine-protein kinase 
participating in mTOR signaling 
Nucleophosmin   83  Proto-oncogene and wide-substrate 
chaperone 
Striatin-4   66  Scaffolding protein for 
calmodulin. Also binds 
phosphatase 2A 
Nicotinamide 
phosphoribosyltransferase  
 64  NAD biosynthesis pathway 
Vacuolar protein sorting-
associated protein 4A  
 61  Membrane fission for endosomal 
sorting 
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Table 4-5. Mass-spectrometric analysis of immunopurified iNOS (Band 5) 
 
Protein   Mowse score  Function 
Calmodulin   797  Calmodulin-Ca
2+
control activity of 
a large number of enzymes 
especially kinases and 
phosphatases, ion channels and 
other proteins 
Calmodulin-like protein 3   143  Similar to calmodulin; gets 
induced by TGF-β1 
Selenoprotein H   77  Cell redox homeostasis 
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probability of matching N peaks by random chance. A protein sequence will be assigned 
a high Mowse score, with the high frequency of matched peaks or when a peak is 
exclusive. 
 
The majority of the proteins immune-precipitated with iNOS were involved in 
protein sorting, processing and folding. Several proteins, including 78 kDa glucose-
regulated protein, are known to be the components of unfolded protein response (UPR) 
implying that the pathway gets activated in an iNOS- dwelling system or generally in an 
inflammatory profile. Also, several proteins were found to be involved in various 
pathological conditions and few could link iNOS and IBD manifestations. For example, 
catenin beta-1 has been linked to the development of colorectal cancer and another 
protein E3 UFM1-protein ligase acts as a tumor suppressor and negatively regulates NF-
kappaB transcription factor activity, which acts canonical to iNOS-upregulation, PP2A 
subunit B isoform B55-alpha can regulate dephosphorylation of the oncogene P53, 
MAPKAP kinase 5 is a tumor suppressor gene of mTOR pathway and nucleophosmin is 
proto-oncogenic. This is important, as it is already known that IBD patients are at a 
higher risk of developing colorectal cancer.  
 
Several other proteins e.g., GLUD1, 78 kDa glucose-regulated protein, were 
related to glucose metabolism or sensing. A recent report mentions the association of 
iNOS with low-order inflammatory states such as obesity-linked Type-2 diabetes (144). 
A major proportion of the protein was directly related but not limited to iNOS-pathway 
which include endoplasmin, serine/threonine-protein kinase TBK1, sulfhydryl oxidase 2, 
dermcidin, interleukin enhancer-binding factor 3, serine/threonine-protein kinase 38, 
insulin-like growth factor 2 mRNA-binding protein 3 to name a few.  
 
Immunoprecipitation of calmodulin was interesting as iNOS is Ca
2+
 insensitive 
and calmodulin-regulation independent. Although, it is known that iNOS binds to 
calmodulin, with the abundance of iNOS within an inflammatory system it is possible 
that iNOS acts as calmodulin scavenger and modulate several important calmodulin-
regulated pathways. These results might be valuable in designing studies that center 
iNOS-dependent pathways in inflammatory disorders and explain many phenotypes 
associated with these diseases.  
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CHAPTER 5.    DISCUSSION 
 
 
Pathophysiology of IBD-associated diarrhea is not clearly understood, and new 
molecular targets for its amelioration need to be identified. Spatial restriction of multiple 
proteins in the form of a macromolecular complex enables a tight and fine-tuned 
regulation of protein function. The goal of this study was to uncover a macromolecular 
interaction that is constituted and contributes to diarrhea in IBD and that may provide 
opportunities for possible therapeutic interventions. 
 
 
Pathological Roles of iNOS  
 
NO is an important cell signaling molecule which acts as a mediator of several 
physiological functions such as e.g. neurotransmission, smooth muscle relaxation, wound 
repair and immunomodulation (68). However, the physiological benefits are limited to 
NO being synthesized when required for a brief period lasting up to few minutes (145). 
When there is chronic NO production, it becomes pathophysiological. There is a 
prevailing notion that iNOS upregulation is a cytoprotective response to an inflammatory 
challenge. However, as NO production by iNOS is sustained it becomes cytotoxic. iNOS 
function is now being implicated in the pathogenesis of a number of neurodegenerative 
disorders such as amyotrophic lateral sclerosis, Alzheimers and Parkinson diseases, 
cardiovascular diseases such as atherosclerosis and lung disorders such as chronic 
bronchitis, asthma and emphysema, and metabolic disorders such as obesity-linked 
insulin resistance. Many aspects for a role of iNOS in maintenance of an inflammatory 
profile have been shown. Also, pharmacological manipulations to inhibit iNOS function 
and knockout of iNOS in experimental colitis models and emphysema models have been 
shown to lead to resolution of inflammation (112, 141).  Noticeably, the temporal 
resolution of NO-mediated effects was critical to achieve consistency in these studies. 
However, there have been conflicting reports on the role of NO in water and electrolyte 
secretion in colitis (112).  
 
 
Compartmentalized NO-cGMP Signaling 
 
Very few studies have reported compartmentation of NO-cGMP signaling. We 
demonstrated that iNOS forms clusters near the plasma membrane in UC-affected gut 
epithelial cells. Dimerization of iNOS is a prerequisite for its function. It is quite possible 
that the clusters are comprised of iNOS multimers representative of a functional state of 
iNOS in UC-affected tissue. Previous data show that NOS activities can be regulated 
through protein–protein interactions and lipid modifications by governing their specific 
intracellular locations and also the downstream events will be dependent on the amounts 
of NO synthesized (33). For example, sGC gets stimulated with the nanomolar amounts 
of NO, while peroxynitrites start getting synthesized in the micromolar range (33).  All 
these factors will critically control the spatiotemporal regulation of the NO-cGMP 
pathway. We demonstrated a high-affinity interaction of iNOS with the PDZ-scaffolding 
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protein NHERF2. A consistent observation with PDZ proteins is their predominant 
association with plasma membrane and their unique binding specificities contributing to 
formation of distinct complexes (43). This organizational capacity of PDZ proteins has 
also been instrumental in recruiting many cytosolic proteins to the membrane and 
mediating vectorial functions (69, 70). It is highly unlikely that large multiprotein 
signaling complexes assemble randomly. The protein expression and localization is 
spatiotemporally coordinated, further aided by specific post-translational modifications 
(146). Palmitoylation of NOS2 on Cys3 as well as interaction with the PDZ-proteins 
CAP-70 or EBP50 is essential to mediate its apical targeting (69, 70, 147). Also, these 
interactions resulted in increased NOS2 dimerization essential for enzyme function (69). 
It is very likely that iNOS-NHERF2 interaction will determine the plasma membrane 
localization of iNOS in IBD where it can be involved in vectorial physiology. The 
pathophysiological relevance of iNOS-NHERF2 interaction at the apical plasma 
membrane was demonstrated using PLA. This is a first demonstration of protein-protein 
interaction in a human disease tissue where the sample comprises of the UC-affected and 
unaffected areas of the same patient. It is quite possible if the interaction between iNOS 
and NHERF2 is compromised the iNOS potency to exacerbate disease pathology would 
decrease. 
 
It is conceivable from the fact of CFTR expression levels being unaltered in UC 
as demonstrated with heat analysis of mRNA expression in human biopsies and 
immunohistochemistry in UC-affected biopsies, that CFTR hyperactivation as 
hypothesized in UC is more a regulatory phenomenon than mere increase in the protein 
expression level. We demonstrate that CFTR regulation in IBD happens in the form of 
CFTR being functionally coupled to iNOS in restricted microdomains at the plasma 
membrane. It also needs to be emphasized that proximity of a cGMP-generating system 
(iNOS and GC) needs to be proximal to the cGMP-effector system (PKG and CFTR) for 
a compartmentalized regulation which is demonstrated in the current study to be achieved 
in the form of a macromolecular signaling complex.  
 
 
Diarrhea in Inflammatory Bowel Disorders 
 
Many surface proteins such as bacterial receptors and transporters, and 
scaffolding proteins have been identified to increase IBD susceptibility. A list of the 
selective IBD susceptibility genes is shown in Table 5-1. Identification of these 
susceptibility factors partially explain the molecular phenotype of IBD and has 
immensely contributed in dissecting out the mechanisms that lead to IBD. However, there 
is a huge lack of information about the interplay of various factors that cause IBD which 
makes it still challenging to be managed. 
 
Diarrhea in IBD presents a big obstacle for its effective management. Diarrhea is 
a consequence of dysfunctional homeostasis when pro-absorptive and anti-secretory 
mechanisms fail to be compensated. Net Na
+
 absoprtion and Cl
−
 secretion into the lumen 
set the osmotic gradients for hydro flux. Thus, it is critical to understand how Na
+
 
absorption and active Cl
−
 secretion may get disturbed and imbalanced in IBD and cause  
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Table 5-1. IBD susceptibility genes 
 
Gene   Implications  References 
NOD2/CARD 15  Intracellular bacterial 
receptor 
 (148, 149) 
NOD1/CARD 4  Intracellular bacterial 
receptor 
 (150) 
IL23R, TNFSF15, 
STAT3, IL12B, CCR6 
and JAK2  
 Interleukin and related genes   (151) 
OCTN1/N2  Organic Cation Transporters  (152) 
MDR1  ABC-transporter  (153) 
CFTR   ABC-transporter  (105) 
DLG5   PDZ protein  (154) 
GPX1, GPX2 
ATG16L1, IRGM 
 Peroxidases 
Autophagy  
 (151) 
(155) 
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diarrhea. Net Na
+
, Cl
−
 and water absorption has been found to be reduced in UC patients 
and in patients with active CD. Decreased Na
+
 absorption is deduced to be majorly a 
consequence of down-regulated expression of Na
+
 transporters and their regulatory 
proteins which include NHE1 and 3 (excluding NHE2), aldosterone responsive β and γ-
subunits of ENaC, Na
+
/K
+
-ATPase-α, and NHERF proteins (156, 157). Also, NHE1 & 
3,β-ENaC, and NHERF1 & 2 were found to be similarly down-regulated in experimental 
colitis models (157). Additionally, NO could dose-dependently inhibit NHE3 activity in 
Caco-2 cells (158). NHE3 couples strongly with NHERF proteins that inhibit the channel 
function through cellular messengers-cAMP, cGMP and calcium and NHERF2 has been 
found to regulate plasma membrane levels of NHE3 (159, 160). However, the 
involvement of NHE3-mediated Na
+
 absorption and its dysregulation in NO-pooled IBD-
affected mucosa would still be debatable with the precarious consideration of the fact that 
NHE3 is poorly expressed in the colonic mucosa (161) and therefore, will have minimal 
contribution towards UC-associated diarrhea. Speaking of Cl
- 
secretory mechanisms in 
IBD, the Cl
-
-HCO3
-
 exchanger down-regulated in-adenoma (DRA) present on the apical 
membrane has reduced mRNA and protein levels in UC (156). However, very little data 
exist on supporting the contribution of active anion secretion in IBD-associated diarrhea. 
Also, the proinflammatory cytokines which also have been shown to play important role 
in diarrhea failed to consistently affect anion secretion (103, 156). However, it needs to 
be understood that IBD is a complicated disorder with innumerable pathological events 
taking place concurrently. Also, the process of fluid secretion across the mucosal 
epithelia is highly synergistic. Therefore, it is hard to functionally dissect out individual 
contributions to electrolyte abnormalities in a whole ensemble of transporters in the 
affected tissue. CFTR is a dominant player of the fluid  secretory pathway of the gut to 
the extent that CF mice did not secrete fluid in response to cholera toxin and they suffer 
from meconium ileus (90). Therefore, how CFTR behaves functionally in IBD is critical 
to be elucidated. Alterations in the mRNA or protein levels of CFTR have not been 
conclusively determined. We demonstrated a mechanism in which CFTR gets regulated 
in an iNOS-governed cGMP microdomain which ultimately contributes to diarrhea in 
IBD. We demonstrated the concept in vitro by inducing iNOS levels in response to 
cytokine challenge (cytomix) in colon epithelial cells and stimulating CFTR Cl
-
 channel 
function in the presence of a cGMP-elevating agent. Further the colocalization studies in 
polarized colon epithelial cells confirmed that proximity of CFTR to iNOS at the apical 
plasma membrane is the molecular basis of iNOS-dependent potentiation of CFTR Cl- 
channel function. 
 
 
PDZ-scaffolds in the Spatiotemporal Regulation of CFTR 
 
NHERF2 has been demonstrated to be acting as a GKAP for cGKII for the 
cGMP-mediated regulation of NHE3 (30). Also, cGKII is known to be the isoform to 
mediate cGMP-responsive activation of CFTR. It is quite possible that NHERF2 exhibits 
dual role of assembling CFTR and iNOS at the plasma membrane as well as functioning 
as GKAP in the complex to spatiotemporally regulate CFTR function. NHE3 inhibition 
was specific to NHERF2-cGKII complex as NHERF1 could not compensate for the 
effect. The likely reason for NHERF1 to not to be able to constitute CFTR-iNOS 
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complex in IBD, although, NHERF1 is a common binding partner for both the proteins, 
is because of its inability to function as GKAP and also may be due to the subtle 
differences in their locations or squences (30). Therefore, it is conceivable that deficiency 
of NHERF2 would impair CFTR-iNOS complex formation and ameliorate diarrhea in 
colitis. Using DSS-induced colitis, we demonstrated in vivo that Nherf2
-/- 
mice are 
partially protected against diarrhea as indicated by reduced weight loss, intestinal fluid 
secretion, and wet/dry weight in the Nherf2
-/-
 mice. Also, the overall pathological features 
of DSS colitis improved in Nherf2
-/- 
mice as suggested by histological examination. This 
observation may pertain to the partial failure of iNOS to be properly localized inside the 
cell in the absence of NHERF2 so that the debilitating effects of iNOS function on 
mucosal integrity are mitigated.  The biological significance of NHERF proteins in 
mediating highly compartmentalized regulation of CFTR was recently recapitulated in 
various PDZ-protein knockout models (49). Despite the fact that NHERF proteins exhibit 
high sequence homology, overlapping tissue expression and subcellular localizations and 
are predicted to be redundant based on physiological normalcy of selective knockouts, 
their deficiencies produced discrete phenotypes of CFTR function. Fsk-mediated 
stimulation of CFTR-dependent bicarbonate secretion was highly reduced in Nherf1 
-/- 
and β2-AR agonist failed to stimulate CFTR function altogether (49). Nherf2 
-/- 
mice 
exhibited higher Fsk-stimulated CFTR bicarbonate secretion and the accounting 
mechanism was found to be LPA- mediated inhibition of CFTR function which requires 
NHERF2 scaffolding. Also, it was concluded that NHERF1 and NHERF2 can function 
independently of one another. Ablation of PDZK1 had no effect on basal and Fsk-
stimulated CFTR secretions. PDZK1 couples CFTR and MRP4 in a macromolecular 
complex and MRP4 inhibition augments CFTR Cl- channel function. Based on this 
observation, Pdzk1
-/-
 mice should have increased CFTR function. However, it is 
important to consider that MRP4 regulates CFTR function in a highly compartmentalized 
manner. Therefore, CFTR potentiation in response to Fsk which causes massive CFTR 
activation can easily mask compartmentalized activation of CFTR in the CFTR-PDZK1-
MRP4 complex and therefore, Fsk is not an ideal reagent to conclude for the loss of 
compartmentalized-downregulation of CFTR function in Pdzk1
-/-
 mice. Additionally, the 
studies were performed in the duodenal tissue which expresses very small amounts of 
MRP4. 
 
 
CFTR within the NO-governed Compartments 
 
We observe that if iNOS function is inhibited within the complex with the iNOS-
inhibitor (L-NIL) in DSS-induced colitis, diarrhea is attenuated. However, the effect 
observed was small which might be due to the nature of the mechanism by which iNOS 
activates CFTR, which is a highly compartmentalized signaling. Whether CFTR within 
the complex is subject to NO-mediated S-nitrosylation, a common NO-mediated post-
translational modification of the protein targets, and be regulated by the process is a 
matter of contemplation and further studies. The process of S-nitrosylation would involve 
nitration of tyrosine residues, which is usually a molecular consequence of high 
concentration of NO, a process that will accelerate CFTR degradation (162). However, 
this does not reconcile with the augmentation of CFTR function and unaltered protein 
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expression in IBD-affected vs. normal mucosal tissue. It is quite possible that the amount 
of NO within the CFTR-iNOS micro-compartments is not sufficient to induce S-
nitrosylation as NO is quickly neutralized by sGC in close proximity. The physiological 
concentrations of S-nitrosoglutathione (GSNO), the endogenous NO-donor and 
bronchodilator, has been shown to increase expression, maturation, and function of both 
the wild-type and the ∆F508 CFTR (162). Whether S-nitrosylation of CFTR is involved 
in GSNO-mediated effects is still not established. However, the mechanisms have been 
broadly elucidated to be cGMP-dependent and independent (163). This aspect of iNOS 
mediated regulation of CFTR in IBD would be a matter for future investigation.  
 
 
Dissolution of Protein-protein Complexes as a Potential Therapy for IBD 
 
Given the fact that the molecular composition of CFTR-containing complexes has 
been shown to significantly influence the secretory profile of the gut and that it can also 
culminate in a pathological condition, modulating such macromolecular associations can 
be a valuable therapeutic approach. Also, with the restriction of mechanism within the 
complex, this approach can be highly specific. Administration of a cell permeable LPA2-
specific peptide could disrupt the CFTR-NHERF2-LPA2 structural and consequently, 
functional integrity. Also, inclusion of a competing peptide for MRP4-CFTR interaction 
attenuated MK571 (an MRP4 inhibitor) - induced potentiation of CFTR function (5). Our 
lab recently identified a cell-permeable, small-molecule compound, CO-068, that 
preferentially inhibits LPA2–NHERF2 interaction and augments CFTR activity in Calu-3 
cells and CFTR-dependent fluid secretion from pig tracheal submucosal glands (164). 
Also, recent studies in our lab and by others have demonstrated that the functional rescue 
of ∆F508-CFTR depends upon the macromolecular associations of the mutated protein 
and it is quite possible that several drugs known to correct mutant protein functional 
deficiencies would involve modulation of protein-protein interactions of CFTR (165). 
Recently, a NHERF1-mediated complex of chemokine receptor CXCR2 with PLC-β2 has 
been shown to regulate neutrophil infiltration during inflammation (166). Also, addition 
of CXCR2-specific peptide (containing the PDZ motif) was found to suppress 
neutrophilic chemotaxis and transepithelial migration of potential therapeutic relevance 
to inflammatory disorders such as colitis, chronic lung inflammation and atherosclerosis 
(166). Therefore, in our opinion specific disruption of iNOS-NHERF2 interaction will 
likely attenuate UC-associated diarrhea and improve one of the most common symptoms 
of UC. 
 
Although it is tempting to speculate that regulation of CFTR function through 
iNOS-elicited cGMP signaling will be a general mechanism in other inflammatory 
phenotypes such as lung inflammation and pancreatitis wherein all these proteins are 
present, we think extra caution should be exercised for such generalization since these 
phenotypes largely depend upon the organ type. However, given the many similarities 
shared by UC and related inflammatory disorders of the gut such as Crohn’s disease and 
diverticulitis, our findings will help understand the associated diarrheal phenotype. 
In short, our findings will advance the understanding of mechanisms accounting for the 
diarrheal manifestations in IBD and help identify new targets and approaches to control 
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the disease. Our study also has important implications for targeting other forms of 
gastrointestinal inflammation. 
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